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ABSTRACT 
An exciting and novel concept of tissue engineering and 
morphogenesis is the generation of bone by the implantation of 
smart biomaterials that in their own right can induce a desired and 
specific morphogenetic response from the host tissues without the 
addition of exogenously applied bone morphogenetic and 
osteogenic proteins (BMPs/OPs). Members of the transforming 
growth factor-∃ (TGF-∃) superfamily of proteins are powerful 
inducers of bone formation. 
 
Disks of four different types of biomaterials were prepared by the 
Council of Scientific and Industrial Research (CSIR) Materials and 
Technology (MATTEK) group, Pretoria, South Africa. The disks 
were 25mm in diameter and 3mm in thickness and had 69 
concavities on one planar side and 25 on the other planar side. 
The depth of each individual concavity was equal to half the 
diameter of that particular concavity.   
 
Phase pure hydroxyapatite (HA) with a calcium/phosphorus 
(Ca/P) molar ratio of 1.67 was prepared by a solid-state reaction 
between Merck tri-calcium phosphate (TCP) [Ca3 (PO4 )2 ] and 
Univar calcium hydroxide [Ca(OH)2 . Types 1 and 2 samples were 
prepared from hydroxyapatite powders Plasma Biotal, batch P120 
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(Type 1) and HAOM 21 (Type 2). Types 3 and 4 samples were 
prepared from degradable biphasic powders consisiting of a 37 
mass percentage TCP mixture with 63 mass percent HA. Type 4 
samples differed from the Type 3 samples in that large 
agglomerates of TCP and of HA were separately formed prior to 
pressing. These agglomerates were then mixed homogeneously 
and then pressed into discs that were sintered. 
 
All the samples were sintered at 1020 oC for 1 hour using a ramp 
rate of 1.5 oC/minute. This was also a thorough sterilization 
treatment process. From the furnace the samples were 
immediately transferred in closed containers to a laminar flow 
cabinet where filtered air flowed over them. The samples were 
then transferred into envelopes of Sterilpeel that were immediately 
sealed in a thermal sealer, all the time untouched by hand.  They 
were taken to the Bone Research Laboratory where they were 
autoclaved at 121oC for 20 minutes. 
 
The disks were implanted heterotopically in the rectus abdominis 
muscle of 6 baboons and harvested on days 30, 90 and 180 post-
implantation. A total of 64 disks were implanted, 16 per animal per 
time period on days 30 and 90 post-implantation. For the 180 days 
time period, only Type 2 and Type 4 substrata were implanted, 8 
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disks per animal. Harvested tissues were subjected to alkaline 
phosphatase, histology, immunohistochemistry and Northern blot 
analyses to determine whether the spontaneous induction of bone 
that occurs only in the concavities is due to trapped BMPs/OPs 
from the circulation or site and local expression of BMPs/OPs 
within the concavities. 
  
The alkaline phosphatase activity was generally low in tissues 
generated in concavities of the different substrata. The activity 
was relatively higher on 30 days compared to 90 days and was 
almost undetectable on 180 days. The activity expressed by type 
1 samples on day 30 was significantly higher at 5% probability 
level compared to 180 days. The morphological and histological 
results of all substrata on 30 days revealed invasion of 
fibrovascular tissue and angiogenesis within the concavities. On 
day 90, there was evidence of spontaneous induction of bone 
formation in concavities of Types 2 and 4 but not in Types 1 and 
3. On 180 days also there was induction of bone in concavities of 
Types 2 and 4. Bone was only observed within the concavities 
and never on planar surfaces between the concavities. The 
distribution of induced bone was variable in the concavities of the 
same substratum as measured histomorphometrically. BMP-3 and 
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OP-1 were immunolocalised at the interface of the substratum in 
concavities of Type 2 and Type 4.  
 
Northern blot analyses of tissues generated within the concavities 
of the various substrata showed clear differences in the mRNA 
expression of the osteogenic markers including BMP-3, OP-1 and 
Collage Type IV. Type II collagen and TGF1 were however, not 
expressed in all the different time periods.   
 
The results of this study suggest that the induction of bone within 
the concavities is due to the expression of BMP/OP family 
members within the concavities. Furthermore the results suggest 
that particle size also play an important role since bone formation 
was only only found in biomaterials with fine distribution of 
particles as compared to biomaterials with coarse particles. 
Further studies need to be carried out to give final insights into the 
spontaneous induction of bone formation within porous biomimetic 
matrices implanted extraskeletally in adult primates of the species 
Papio ursinus. 
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1.0 INTRODUCTION  
1.1 Initiation of bone formation 
Bone has a capacity to repair and regenerate. Lacroix (1945) 
observed that alcoholic extract of the rabbit long bone 
cartilagenous epiphyses promoted bone formation when 
implanted intramuscularly or subcutaneously. Based on this 
observation, the author hypothesised that in bone there may be 
substances that might initiate bone growth, which he named 
osteogenins. This was followed by the studies of Urist (1965) and 
Reddi and Huggins (1972) who first used in vivo assays to study 
bone-inductive properties of demineralised bone matrix and then 
stimulated many other groups to contribute to the growing 
knowledge of the molecular and cellular signals involved in 
endochondral bone formation 
 
Bone tissue is a complex organ composed of differentiated cells 
called osteoblasts, which are derived from mesenchymal 
progenitor cells (Ohgushi et al., 1993). The major constituent of 
bone is calcium hydroxyapatite, which is composed of calcium 
phosphate laid into a framework of connective tissue (Yamashita 
et al., 1994). Bone also consists of trace elements (Driessens and 
Verbeeck, 1990).  
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The studies of Urist (1965) and Reddi and Huggins (1972) have 
led to the postulation of a bone morphogenetic protein/osteogenic 
protein (BMP/OP) complex in the bone matrix (Urist et al., 1984; 
Sampath et al., 1987). Intramuscular implantation and 
subcutaneous implantation of demineralised bone matrix (DBM) 
led to bone formation by induction in the recipient animals as 
reported by Urist (1965) and Reddi and Huggins (1972), 
respectively. To investigate whether the factor or factors 
responsible for bone formation in the demineralised bone matrix 
was the combined action of several factors present in bone, a 
separate protein, or a new unknown family of proteins, naturally-
derived BMPs/OPs were isolated from the demineralised bone 
matrix and purified to provide information for amino acid 
sequences (Wang et al., 1988; Luyten et al., 1989). This work led 
to expression cloning and characterisation of the recombinant 
human BMPs/OPs (Wozney et al., 1988). 
 
The purification and molecular cloning of the BMPs/OPs has set 
the stage for novel therapeutic approaches to correct congenital 
and acquired craniofacial and orthopaedic conditions (Ripamonti 
and Vukicevic, 1995). Furthermore, the purification of BMPs/OPs 
has led to the cellular and molecular dissection of bone 
development and regeneration. 
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The first sign that indicates imminent osteogenesis is the 
condensation of mesenchymal and mesodermal cells to form a 
primordium of bone. Bone has a considerable potential for repair 
and regeneration and the stages of fracture repair recapitulate the 
sequential developmental stages of embryonic endochondral 
bone development (Reddi, 1992; Wozney, 1992; Reddi, 1994). A 
cellular cascade that mimics embryonic endochondral bone 
development can be induced locally by implantation of 
demineralized bone matrix (DBM) in extra-skeletal sites (Urist, 
1965; Reddi and Huggins, 1972; Reddi, 1981).  
 
The cellular and biochemical events of this matrix-induced 
endochondral bone cascade have been well endorsed (Reddi and 
Huggins, 1972; Reddi, 1981). The developmental cascade of 
matrix-induced endochondral bone formation consists of 
chemotaxis and attachment of mesenchymal stem cells to the 
matrix, proliferation of mesenchymal progenitor cells followed by 
cartilage differentiation, which in turn is followed by calcification of 
the cartilage, chondrolysis and finally hematopoiesis in the newly 
formed ossicle (Reddi, 1981). These events are sequentially 
coordinated in a rigorous fashion by members of the transforming 
growth factor-beta (TGF-β) and bone morphogenetic 
proteins/osteogenic proteins (BMP/OP) families.  
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In rodents, the cascade of bone formation is as follows (Reddi 
1981): Fibronectin deposition on the matrix, facilitating cell 
attachment, proliferation of mesenchymal cells follows, resulting in 
chondroblast differentiation; appearance of chondrogenic matrix 
as shown by sulphate incorporation into proteoglycans and 
appearance of chondrocytes. The beginning of angiogenesis and 
cartilage resorption or chondrolysis then follows. New bone 
formation in association with calcium incorporation occurs after 
differentiation of osteoblasts, followed by extensive bone 
remodeling with hematopoietic marrow formation as evidenced by 
iron incorporation. 
 
Embryonic events give rise to five types of cells which are 
responsible for the production of the five mineralised tissues in the 
body. These are: osteoblasts producing bone, chondroblasts 
producing cartilage, odontoblats producing dentine, cementoblasts 
producing cementum and ameloblasts producing enamel (Urist, 
1980). During development and adult life, osteoblasts and 
osteoclasts continuously replace old bone with new bone through 
the process of bone remodeling (reviewed by Parfitt, 1994). The 
cycles of bone deposition and resorption are tightly linked (Harris 
et al., 1969) thereby maintaining skeletal integrity, bone mass and 
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shape. This concept postulates that bone resorption, which occurs 
in order to release calcium for homeostatic needs or to reshape 
bone structure to fit better its mechanical function, is followed by 
bone formation which under balanced conditions, restores the lost 
bone. 
 
 
 
1.2 Hydroxyapatite and bone formation 
Hydroxyapatite (HA) is an important biomaterial because of its 
affinity for BMPs/OPs which is employed for the chromatographic 
purification of BMPs/OPs extracted from the bone matrix and has 
been exploited for the construction of the delivery systems 
following BMPs/OPs' chromatographic adsorption onto porous 
hydroxyapatite (Ripamonti et al., 1993b).  
 
Hydroxyapatite is desirable as a bone substitute because it is the 
prototype of human bone and teeth (Sasano et al., 1995) 
comprising 60-70% of the bone matrix and 98% of dental enamel 
(Jarcho, 1986). The desirability of alternatives to the currently 
available, usually metallic, uniformly dense and harder than bone 
implants has been the source of many intensive investigations in 
the research laboratories on biomaterials around the world. A 
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specified advantage of materials fabricated in a porous 
configuration is the potential for ingrowth of tissue such as to 
provide biological fixation of the hard tissue implants (Chiroff et al., 
1975; Feldman and Estridge, 1984). Various techniques for the 
fabrication of materials have been devised. Extensive alterations 
of various hydroxyapatite porosities have been accomplished 
(Hulbert et al., 1970; Ripamonti et al., 1999).   
 
Denissen et al.  (2000a) conducted experimental and clinical 
studies to evaluate the effect of highly biphosphonate-complexed 
hydroxyapatite implants on osteoconduction and repair in alveolar 
bone. They used porous hydroxyapatite implants pretreated with 
10 (-2) M bisphosphonate solution and implanted in goats. The 
authors concluded that the study contributed to the understanding 
of the biological properties of hydroxyapatite implants as carriers 
for the bone-modulating agent biphosphonate. The study also 
suggested that normal osteoconduction and repair occurred in 
alveolar bone around the highly bisphosphonate-complexed 
hydroxyapatite implants (Denissen et al., 2000a).  
 
Denissen et al. (2000b) performed another study to evaluate the 
effects of biphosphonate-complexed hydroxyapatite implants on 
osteoconduction and repair in rat tibiae. Indeed their results 
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suggested that normal osteoconduction and repair occurred in and 
around the highly bisphosphonate-complexed hydroxyapatite 
implants in rat tibiae; these results support the previous study.  
 
Allumina substrata are also used in total joint replacement mainly 
because of their inertness, excellent biocompatibility and high 
wear resistance (Christel, 1992; Cooke, 1992; Heimke, 1990; 
Hulbert, 1990) although alumina does not bond to bone as well as 
HA. The problem of bonding between alumina and bone was 
solved by coating porous alumina substrata with HA (Takaoka et 
al., 1996). The HA-coated alumina has a high mechanical strength 
as well as bioactive properties. HA coating on other implants has 
been previously reported and it has been shown that HA coating 
stimulates bone formation (Cook et al., 1986; Cook et al., 1987; 
Dhert et al., 1991; Furlong, 1991; Geesink, et al., 1988; Soballe et 
al., 1989).  
 
 
1.3 Calcium phosphates and bone formation  
The calcium phosphate bioceramic materials are described as 
sintered polycrystalline solids whose structure is characterized by 
distinct individual crystals held together by grain boundary phases, 
 32
a typical result of the solid phase reaction during sintering (Osborn 
J F, 1985). 
 
Tricalcium phosphate (TCP) is an important biomaterial that can 
be used as a bone graft substitute.TCP was reported to be 
comparable to hydroxyapatite in terms of biocompatibility and 
osteoconductivity in the presence of marrow cells (Ohgushi et al., 
1990; Ohgushi et al., 1993).  TCP is an important biomaterial 
because of its biodegradability.  The concept that calcium 
phosphate biomaterials are safe and effective for a variety of 
clinical applications has been well documented (Metsger et al., 
1982; De Groot, 1980; Jarcho, 1981). Two forms of calcium 
phosphate substrata, HA and TCP are the most commonly used. 
TCP, unlike hydroxyapatite, is not a natural component of bone 
mineral but is chemically similar to HA (Jarco, 1986).  
 
Calcium phosphate biomaterials are the most biocompatible 
synthetic substances known for use in hard tissue implantations 
because they are devoid of local or synthetic toxicity, do not elicit 
inflammatory or foreign body reactions, can become functionally 
integrated with natural bone with no fibrous tissue encapsulation 
and can cause no alteration of normal bone mineralization 
processes (Jarcho, 1986). Moreover, another compelling feature 
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of calcium phosphate is their ability to become strongly bonded to 
living bone. This phenomenon of bonding has been observed and 
reported in many studies (Dessen et al., 1981; Jarcho, 1981; 
Jarcho, 1977; Kato et al., 1979; Ogiso, 1983; 1980; Tracy and 
Doremus, 1984). Probably the exceptional biocompatibility of 
these biomaterials is attributable to their being primarily composed 
of calcium and phosphate ions, the most common constituents of 
vertebrate hard tissue systems (Jarcho, 1986). Calcium 
phosphate biomaterials provide a physical matrix suitable for 
deposition of new bone and can display growth-guiding properties 
that cause bone to extend its growth into areas it would not 
otherwise occupy (Itatani and Marshall, 1984; McDavid et al., 
1979, Pieench, 1982).  
 
Calcium phosphate substrata have also demonstrated the ability 
to maintain bone bulk in areas where bone resorption normally 
takes place. Several investigators have noted that HA implants 
are able to prevent post extraction alveolar ridge resorption in 
much the same manner as do autogenous tooth roots (Jarcho, 
1986). When placed either sub- or perigingivally in fresh extraction 
sockets of dogs, these implants become firmly ankylosed via the 
bone-bonding phenomenon while maintaining and increasing the 
height of surrounding bone relative to unimplanted control 
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extraction sites (Jarcho, 1986). Calcium phosphate substrata are 
also well tolerated by soft tissues, wherein they are usually 
surrounded by a quiescent fibrous tissue capsule (Jarcho, 1986). 
The factors governing bioresorbability of calcium phosphate 
biomaterials are not fully understood, but appear to include 
chemical composition and porosity of the particular form of 
calcium phosphate. It is thought that bioresorption can result from 
both chemical dissolution in biologic fluids and cell mediated 
processes such as phagocytosis (De Groot, 1983; 1980; Jarco, 
1981). The surface area of calcium phosphate substratum is also 
important in determining bioresorption. High density biomaterials 
posses a much smaller surface area than porous ones and have 
thus a lesser resorbability.  
 
The use of porous forms of calcium phosphate substrata offers 
several attractions conceptually. Despite the fact that porous 
implants are more easily carved than dense ones and also that 
the pores can provide a mechanical interlock leading to a firmer 
initial fixation of the implant during the immediate post operative 
phase, major and fundamental questions remain as to the 
suitability of porous implants for permanent implant applications. 
Porous implants have very little strength and depend on bone 
ingrowth to achieve a mechanically viable restoration.  
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Much experimental evidence attests to the ability of calcium 
phosphate biomaterials to bond to bone. Okumora et al. (1991); 
Fujiu and Ogino, (1984); Kitsugi et al., (1989). Hench et al. (1971) 
studied the hydroxyapatite-bone bonding mechanism at the 
interface between bone and glass. He found that the presence of 
crystals of hydroxyapatite on the surface of glass using scanning 
electro microscope (SEM), transmission electron microscope 
(TEM) and X-ray diffraction analysis. The results suggested the 
direct chemical bonding of hydroxyapatite crystals at the interface. 
Subsequently, many investigations of the interface between bone 
and bioactive hydroxyapatite have been performed in a variety of 
techniques. (Holland et al., 1985; Krajewski et al., 1988).  
 
1.4 Hydroxyapatite-induced bone formation in different 
animal models 
Studies using porous hydroxyapatite biomaterials have been 
carried out in different animal models. Ripamonti, (1996) used 
porous hydroxyapatite obtained after hydrothermal conversion of 
the calcium carbonate exoskeleton of coral to induce bone 
formation in the rectus abdominis of adult rabbits, dogs and 
baboons without addition of exogenous BMPs/OPs. The author 
reported minimal amount of bone in dogs and rabbits, and a 
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substantial amount of bone in the baboon (Ripamonti, 1996). In 
rats, implantation of hydroxyapatite both intramuscularly and 
subcutaneously does not result in bone formation (Ohgushi et al., 
1989; Goshima et al., 1991; Yosghikawa et al., 1992; Ohgushi et 
al., 1993).  Bone formation was also demonstrated within porous 
hydroxyapatite implanted intramuscularly in rabbits (Miller et al., 
1991). Osteoinduction has also been observed in rabbit and rat 
models when the porous hydroxyapatite was combined with 
BMPs/OPs (Ripamonti et al., 1992a; Takaoka et al., 1988). 
Formation of bone has also been reported in dogs on implantation 
of porous hydroxyapatite in soft tissue sites (Yamasaki and Sakai, 
1992). Arun et al. (2002) demonstrated osteoinduction upon 
implantation of porous hydroxyapatite in intramuscular and 
subcutaneous sites in sheep. 
 
Kurashina et al (2002) reported ectopic osteogenesis with 
biphasic ceramics of hydroxyapatite and tricalcium phosphate in 
rabbits. The authors implanted porous calcium phosphate 
ceramics consisting of hydroxyapatite and tricalcium phosphate 
with different ratios intramuscularly in rabbits for six months. Their 
results showed bone formation in one type of ceramic while the 
other types showed some degree of degradation but not bone 
formation. They reported that the degradation rate of the 
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biomaterials may be one of the affecting factors in ceramic-
induced osteogenesis. Further more, Yamasaki (1990) found bone 
formation induced by hydroxyapatite ceramic in the dogs’ 
subcutis. Similar results were reported in different animal models 
such as rabbits, goats, pigs, dogs, monkeys, baboons and 
humans (Zhang et al. 1991;  Vagervic, (1992); Toth, (1993); Klein, 
(1994); Green et al. (1995); Yang et al. (1996); Yuan et al. (1997); 
Sires et al. (1997); de Bruijn et al. (1999); Yuan et al. (2000).  
Calcium phosphate ceramics have also been reported to be 
osteoinductive in muscles of dogs (Yuan et al., 2001).  
 
Previous studies have shown that porous hydroxyapatite plays an 
important role as a cell substratum in BMP-induced heterotopic 
bone formation (Ono et al., 1992; Ono et al., 1995; Ono et al., 
1996; Ravaglioli et al., 1992; Ripamonti et al., 1992a; Ripamonti et 
al., 1993b; Ripamonti et al., 1999; Ripamonti et al., 2001). An 
artificial cell substratum requires biochemical, physiochemical and 
geometric properties. The biochemical property involves mainly 
the molecules of the extracellular matrix, which bind to the 
adhesive receptor molecules of the cell surface. The 
physiochemical aspect is involved in the adsorption of cells on the 
substrate surfaces. These two properties have already been well 
documented. Geometry, which refers to the three dimensional 
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shape, porosity, particle size and geometrical configuration in the 
form of repetitive sequence of concavities, on the other hand is 
not yet well understood. The geometry of the substratum has been 
shown to profoundly influence the expression of the chondro- 
osteogenic phenotype in vivo although the mechanisms involved 
are not clearly understood (Reddi and Huggins, 1973; Ripamonti 
et al., 1992a; Sampath and Reddi, 1984; Ripamonti et al., 1999; 
Ripamonti, 2000c)                                                                                                                               
 
Jin et al. (2000) investigated the geometry of the BMPs/OPs 
carriers in bone formation in rats. They used three different types 
of hydroxyapatites, namely, porous particles, porous blocks and 
honeycomb-shaped hydroxyapatites.  These carriers were 
compared in terms of their abilities to initiate osteogenesis when 
implanted subcutaneously with recombinant hBMP-2. Their results 
showed that direct bone formation occurred in porous and in block 
particles of hydroxyapatite while endochondral ossification 
occurred in honeycomb-shaped hydroxyapatite. Cartilage in the 
central zones and bone in the orifice zones of the tunnels of the 
honeycomb-shaped hydroxyapatite were observed at two weeks 
after which the cartilage disappeared and bone formation occurred 
throughout the inner surface of the tunnels of the hydroxyapatite, 
leaving space for capillaries within the tunnels. The authors 
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concluded that the geometry of the hydroxyapatite controls 
vascular capillary invasion and affects cell growth and 
differentiation and thus phenotype expression in the BMP-induced 
heterotopic bone and cartilage induction (Jin et al., 2000). 
 
Manipulation of the geometry and the surface characteristics of 
the substratum and incorporation of specific biological activities 
into biomaterials will result in predictable bone morphogenesis 
and growth for treatment of human bone defects. This 
phenomenon is defined as geometric induction of bone formation 
and will aid in achieving breakthroughs in tissue engineering of 
bone and related tissues for therapeutic osteogenesis in clinical 
contexts (Ripamonti et al., 1999; Ripamonti, 2000c). 
 
1.5 Intrinsic osteoinductive biomaterials 
The use of intrinsic osteoinductive biomaterials including porous 
hydroxyapatite (HA) has been documented (Ripamonti et al., 
1992a; Ripamonti et al., 1993b; van Eeden and Ripamonti, 1994; 
Ripamonti et al., 1999; Ripamonti et al., 2000a Ripamonti et al., 
20001). Further experiments were conducted by Ripamonti and 
co-workers to create and study biomaterials that in their own right, 
when implanted heterotopically in recipient animals, can induce 
specific morphogenetic responses from the host tissue without the 
 40
addition of exogenously applied BMPs/OPs, i.e., biomaterials with 
intrinsic osteoinductive activity (Ripamonti et al., 1999). 
 
The optimal induction of bone formation is dependent on the 
combined action of BMPs/OPs and the insoluble substratum that 
is complementary. The preparation of composites of 
osteoconductive biomaterials with BMPs/OPs results in the 
formulation of osteoinductive biomaterials (Ripamonti and 
Duneas, 1996; Ripamonti et al., 1999). This concept is of great 
significance for future therapeutic applications. The acid test for 
osteoinductivity is the histological evidence of bone formation by 
induction in extraskeletal heterotopic sites of animals.  
 
Ideal biomaterials for tissue engineering of bone should be non 
immunogenic, carvable, and amenable to contouring for optimal 
adaptation to the various shapes of bone defects, providing 
mechanical support when needed (Ripamonti and Duneas, 1996). 
In addition to initiating optimal osteogenesis with relatively low 
doses of hBMPs/OPs, ideal biomaterials should also promote 
rapid vascular and mesenchymal cell invasion to be brought into 
contact with BMPs/OPs previously adsorbed onto the carrier 
(Ripamonti and Duneas, 1996). It should also have the ability to 
remodel and resorb. Materials made of calcium phosphate 
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apatites have to date been the most useful synthetic biomaterials 
for bone replacement therapies (Jarcho, 1981; Hench, and 
Wilson, 1984). They are all capable of osteoconductivity and 
osteointegration to varying degrees depending on preparation and 
specific chemical composition.  
 
Several studies have been performed that establish that some 
porous hydroxyapatite obtained from the calcium carbonate 
exoskeleton of corals can induce bone differentiation in direct 
contact with the hydroxyapatite substratum when implanted 
extraskeletally in adult baboons (Ripamonti, 1990; Ripamonti et 
al., 1993a; Ripamonti, 1996, van Eeden and Ripamonti, 1994). In 
these experiments in heterotopic sites of baboons, bone formation 
was only limited to porous hydroxyapatites in block configuration 
as opposed to identical porous hydroxyapatite in granular and 
particulate configuration. 
  
It is important to differentiate between an osteoconductive and an 
osteoinductive biomaterial. The former does not posses inherent 
osteoinductivity per se, but is capable of guiding and directing 
bone growth at its interface and achieving osteointegration after 
orthotopic implantation (Ripamonti and Duneas, 1996; Ripamonti 
et al., 1999). The latter bears osteoinductivity and its 
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discriminatory bioaction is osteogenesis (Ripamonti and Duneas, 
1996). The generation of bone by the implantation of biomaterials 
that can induce desired and specific responses from the host 
tissues without addition of exogenously applied BMPs/OPs is an 
exciting and novel concept of bone tissue engineering (Ripamonti 
et al., 1999).   
 
The use of biocompatible and bioactive materials for drug delivery 
and tissue engineering has been well documented (Hoffman 1995; 
Ito et al., 1997; Williams, 1997; Graham.1998; Ripamonti et al., 
1999; Wang et al, 1999; Galaev and Mattiason, 1999; Langer, 
2000). These biomaterials have the ability to control biological 
functions by responding to physical, chemical or biological stimuli 
(Hoffman, 1995). This concept has been highlighted for tissue 
engineering of bone by the heterotopic induction of bone 
(Ripamonti et al., 1999) and osteoconduction by porous 
hydroxyapatite in experimental animals (Chang et al., 2000). The 
mechanism behind osteogenesis in these bone induction studies 
appears to be greatly dependent on the nature and the structure 
of the substratum (van Eeden and Ripamonti, 1994; Tsuruga et 
al., 1997; Kuboki et al., 1995; 1998; Murata et al., 1998; Ripamonti 
et al., 1999; Kurioka et al., 1999; Jin et al., 2000).  
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The general background for undertaking such studies is the aim to 
develop biomimetic biomaterials that are specifically designed to 
enable endogenously produced molecular signals to adsorb onto 
the implanted matrix or to intrinsically activate their genes 
(Ripamonti et al., 1999; Ripamonti, 2000c; Ripamonti et al., 2001) 
by the implantation of these structurally correct matrices in sites 
where bone induction is required. The adaptable character of 
these biomaterials makes them more practical and more cost 
effective in their application than devices requiring the 
combination of both carriers and growth factors (Ripamonti et al., 
2001).  
 
1.6 Geometric induction of bone formation 
The effects of matrices on cell differentiation were first 
demonstrated by Reddi and Huggins (1973). They showed that 
the matrices of open and dead-end tube structures had different 
effects on osteogenesis and chondrogenesis. The dead-end tubes 
induced chondrogenesis while the open-end tubes induced 
osteogenesis. The authors suggested that the result was due to 
the higher vasculature in the open tube and that the higher 
oxygen and nutrient supply favored osteogenesis while the lesser 
vasculature in the other tube led only to chondrogenesis (Reddi 
and Huggins, 1972).     
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The critical role of the geometry of the substratum in the regulation 
of cell growth and endochondral bone differentiation has been 
reported previously using different geometric configurations of 
collagenous matrix indicating that the endochondral sequence can 
be greatly altered by the geometry of the inductor (Reddi and 
Huggins, 1973; Reddi, 1974; Sampath and Reddi, 1984).  
 
Ripamonti et al. (1992a) reported that the geometry of the 
substratum had a profound influence on bone induction in rodents. 
The authors delivered BMPs/OPs using non-resorbable porous 
hydroxyapatite in granular and disc configurations. The expression 
of the osteogenic phenotype was exclusively observed in porous 
hydroxyapatite in disc configuration as opposed to granular 
hydroxyapatite with identical pore dimensions even in the 
presence of exogenously-applied BMPs/OPs (Ripamonti et al., 
1992a). van Eeden and Ripamonti later reported the effects of the 
geometry of the carrier on bone formation by comparing porous 
hydroxyapatite in block and granular forms with different pore 
sizes (200 and 500 µm) (van Eeden and Ripamonti, 1994). In this 
study there was higher efficacy of bone induction in the block 
configuration and no bone in the granular form. 
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Monolithic discs of sintered hydroxyapatite with concavities of 800 
and 1600µm diameter on both planar surfaces were implanted in 
the rectus abdominis of adult baboons (Papio ursinus) to 
investigate the geometric influence on bone formation (Ripamonti, 
et al., 1999). Spontaneous initiation of bone proved to be 
regulated by the geometry of the substratum i.e. the concavities. 
This supports a novel concept in tissue engineering of bone, that 
is, substrata with osteoinductive geometric configurations, since 
bone morphogenesis and the generation of marrow depends 
exclusively on the geometry of the HA substratum (Ripamonti et 
al., 1999).  
 
1.7  The TGF-ß superfamily 
The TGF-ß superfamily comprises a large group of structurally 
related signalling proteins that are secreted as dimers and then 
cleaved after an Arg-X-X-X-Arg site to release biologically active 
carboxy-terminal domains containing seven highly conserved 
cysteine residues (Kingsley, 1994). The group consists of BMPs  
(Wozney et al., 1988; Özkaynak et al., 1990; Celeste et al., 1990); 
activins and inhibins (Mason et al., 1985; Forage et al., 1986; 
Mayo et al., 1986; Schwall et al., 1988), the 60 A (Wharton et al., 
1991) the Müllerian inhibitory substance (MIS) (Cate et al., 1996), 
the dpp gene products of Drosophila melanogaster (Padget et al., 
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1987; Ferguson and Anderson, 1992); the vegetal Vg-1 gene 
products of Xenopus Laevis (Weeks and Melton, 1987); the Vg-1 
related analogue of murine Vgr-1 (Lyons et al, 1989); the more 
distantly related growth and differentiating factors (GDFs) (Lee, 
1990; Lee, 1991; McPherron and Lee, 1993; Jones et al., 1992; 
Cunningham et al., 1995), the cartilage derived morphogenetic 
proteins (CDMPs) (Chang et al., 1994) and finally, the TGF-ßs 
themselves (Derynck et al., 1985; Roberts and Sporn, 1990). 
 
 TGF-βs are biologically active peptides whose unique feature is 
to induce anchorage-dependent, non-neoplastic cells to lose 
contact inhibition and to undergo anchorage independent growth, 
a property that can be quantitated by measuring the formation of 
colonies of cells in soft agar (De Larco and Torado, 1978; 
Roberts, et al., 1980; Roberts et al., 1981). TGF-βs were identified 
in human platelets by Assoian et al. (1983) as composed of a 25 
kDa polypeptide made up of two 12.5 kDa subunits held together 
by disulphide linkage. 
 
TGF-βs are released from the cell in inactive complexes that 
require activation (Centrella et al., 1994). To become biologically 
active, they have to be dissociated from the latent complex 
(Gentry et al., 1987). The TGF-β family comprises 5 closely 
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related proteins called TGF-β 1 to –5 (Roberts and Sporn, 1990) 
of which 1 to –3 are mammalian, 4, now known as a new molecule 
called ebaf/lefty-A (Kothapalli et al., 1997) was identified in 
chicken and the isoform -5 in Xenopus laevis. Like BMPs/OPs the 
amino acid carboxyl terminal domain of the TGF-βs is highly 
conserved between species (Roberts et al., 1991).  
 
Active TGF-β contains 9 cystein residues, seven of which are 
conserved within members of the family. TGF-β1 is identical in 
man, monkey, cow and chicken. TGF-β 2 is 71% homologous to 
TGF-β1 and the other TGF-βs share homology in the range of 
64% to 83% with TGF-β1 (Roberts et al., 1991). The mature 
region of TGF-β3 has an approximately 80% identity to the mature 
regions of TGF-β1 and TGF-β2. The precursor regions of the first 
three isoforms share 27% sequence identity (ten Djike et al., 
1988; Derynck et al., 1988). The first three isoforms have been 
found also in human tissues. Wataya-Kaneda, et al. (1994) used 
immunohistochemistry to show that TGF-β2 localisation was 
mainly in the intercellular space of all the layers of the epidermis 
and weakly in the cytoplasm. TGF-β3 was present in the 
subepidermal area of the dermis and TGF-β1 was not observed 
either in the dermis or epidermis. These results suggest that TGF-
β2 and -3 may play a crucial role in the regulation of the human 
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skin function in an epithelial autocrine or mesenchymal -epithelial 
interaction manner.  
   
Members of the TGF-β family have diverse biological activities 
and play critical roles in the migration, proliferation and 
differentiation of a variety of cells during embryogenesis (Heine et 
al., 1987; Pelton et al., 1990), repair and regeneration as well as 
maintenance of tissues during post-fetal life (Roberts and Sporn, 
1990; Derynck, 1994; Kingsley; 1994). TGF-βs were reported to 
play important roles in epithelial-mesenchymal interactions in that 
they enhance the differentiation of epithelial and mesenchymal 
cells (Vukicevic et al., 1996). Lehnet and Akhust (1988); Pelton et 
al. (1989; 1990); Millan et al. (1991); Schmidt et al. (1991) 
reported the temporal and spatial expression of TGF-β isoforms in 
various developing tissues undergoing epithelial and 
mesenchymal interactions such as kidney, heart, hair, palate, 
lung, skin, whisker follicles, teeth and mammary glands. 
Moreover, TGF-β1 is abundantly found in connective tissue, 
cartilage and bone as well as in tissues derived from neural crest 
mesenchyme (Heine et al., 1987).  
 
TGF-β2 has been found in early facial mesenchyme and in 
various epithelial cells (Pelton et al., 1989). Heine et al. (1987) 
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also reported the localisation of TGF-β2 during mesenchyme and 
mesoderm remodeling. TGF-β2 was localized during the formation 
of digits from limb buds, palate formation and heart valves 
formation. de Bortolli et al. (1995) reported the role of TGF-β 
isoforms in epithelial maturation of the developing rat fetal lung. 
Immunofluorescence showed localisation of TGF-β 1,-2, and –3 in 
rat fetal lung fibroblasts.  
 
TGF-β1 knockout mice die in utero and the remainders give in to 
uncontrolled inflammation after birth (Kulkarni et al., 1993). 
Letterio and Bottinger (1998) reported the role of TGF-β isoforms 
in the regulation of the immune system. Their results showed 
evidence for altered development, activation and function of 
various immune populations in knockout mice. TGF-βs increase 
the cytokine-dependence of T cells for survival (Sillet et al., 2001). 
Clark and Coker (1998) demonstrated the role of TGF-βs in 
homeostatic and pathogenic processes and suggested that TGF-
βs may play an important role in the diagnosis and treatment of 
various diseases characterized by inflammation and fibrosis. 
Furthermore, TGF-β has been reported to promote virus 
replication in infected monocytes and peripheral blood 
mononuclear cells under certain in vitro conditions (Lotz and Seth, 
1993). 
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1.8  Bone morphogenetic proteins (BMPs)  
 Bone has a capacity to repair and regenerate. Lacroix (1945) 
observed that alcoholic extract of the rabbit long bone 
cartilagenous epiphyses promoted bone formation when 
implanted intramuscularly or subcutaneously. Based on this 
observation, the author hypothesised that in bone there may be 
substances that might initiate bone growth, which he named 
osteogenins. This was followed by the studies of Urist (1965) and 
Reddi and Huggins (1972) who first used in vivo assays to study 
the bone-inductive properties of demineralised bone matrix and 
then stimulated many other groups to contribute to the growing 
knowledge of the molecular and cellular signals involved in 
endochondral bone formation.  
 
The studies of Urist (1965) and Reddi and Huggins (1972) have 
led to the postulation of a bone morphogenetic protein/osteogenic 
protein (BMP/OP) complex in the bone matrix (Urist et al., 1984; 
Sampath et al., 1987). Intramuscular or subcutaneous 
implantation of demineralised bone matrix (DBM) led to bone 
formation by induction in the recipient animals as reported by Urist 
(1965) and Reddi and Huggins (1972), respectively. To investigate 
whether the factor or factors responsible for bone formation in the 
demineralised bone matrix was the combined action of several 
 51
proteins present in bone, a separate protein, or a new unknown 
family of proteins, naturally-derived BMPs/OPs were isolated from 
demineralised bone matrix and purified to provide information for 
amino acid sequences (Wang et al., 1988; Luyten et al., 1989). 
This work led to expression cloning and characterisation of the 
recombinant human BMPs/OPs (Wozney et al., 1988). 
 
The purification and molecular cloning of the BMPs/OPs has set 
the stage for novel therapeutic approaches to correct congenital 
and acquired craniofacial and orthopaedic conditions (Ripamonti 
and Vukicevic, 1995). Furthermore, the purification of BMPs/OPs 
has led to the cellular and molecular dissection of bone 
development and regeneration. 
 
BMPs/OPs have the ability to singly induce de novo endochondral 
bone formation when implanted in heterotopic sites of 
experimental animals (Reddi, 1992; Wozney, 1992; Reddi, 1994). 
On the basis of characteristics that include amino acid sequences 
in the carboxyl terminal region and their tertiary structure, the 
BMPs/OPs are grouped as a family within the transforming growth 
factor beta (TGF-) superfamily (Wozney et al., 1988; Reddi, 
1992; Wozney, 1992; Centrella, 1994). BMP-1 is the only BMP/OP 
that is not a member of the TGF- superfamily (Kessler, 1996; 
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Reddi, 1996). It is a procollagen C-proteinase, functioning in vivo 
for the proper assembly of collagen within the extracellular matrix 
(Kessler, 1996; Reddi, 1996).  
 
To initiate the biochemical and morphological sequences required 
for tissue engineering of bone, three key components are needed: 
a soluble osteoinductive signal, a suitable insoluble substratum 
that acts as a delivery system and scaffold for new bone to form 
and responding mesenchymal cells capable of differentiation into 
bone cells (Reddi, 1994; Ripamonti and Duneas, 1996; Ripamonti 
and Reddi, 1997).  
 
The ability of BMPs/OPs to induce bone in heterotopic sites is a 
characteristic that has attracted the strong attention of scientists in 
the orthopedic, craniofacial and dental fields in anticipation of its 
clinical applications. To achieve the clinical applications of 
BMPs/OPs, optimal carriers must be investigated and developed.  
 
1.9 TGF-ß and bone formation 
Since their first detection in skeletal tissues, TGF-β family 
members have been investigated as potential regulators of bone 
cell activities. Target cells include cells that participate in various 
stages of bone formation and they may induce primary and 
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secondary effects on bone resorbing osteoclasts (Centrella et al., 
1994). Several lines of evidence have indicated that the secreted 
proteins of the TGF-β superfamily are involved in the local and 
systemic regulation of tissue morphogenesis, including 
skeletogenesis, osteogenesis, cementogenesis and 
nephrogenesis (Wozney et al., 1988; Reddi, 1994; 1997; 1998; 
Ripamonti and Vukicevic, 1995; Vukicevic et al., 1996; 1998; 
Duneas et al., 1998; Ripamonti and Reddi, 1997).   
 
When TGF-β is injected directly to calvariae or to overlying 
periosteal tissues, the bone mass increases in mice and rats 
(Noda and Camilliere, 1989; Marcelli et al., 1990). Marcelli et al. 
(1990) showed that repeated injections of rhTGF-β1 into the 
subcutaneous tissue overlying the calvaria of neonatal mice 
resulted in a marked increase in the periosteal thickness and 
cellularity and stimulation of newly mineralised bone without a 
chondrogenic phase. Beck et al. (1991) reported that topical 
application of TGF-β1 to cartilage in full thickness wounds on 
rabbit ears rapidly induces healing and bone formation. Later 
studies using the rabbit calvarial model showed that defects 
treated with hTGF-β1 were characterized by an increase in 
parameters of bone formation up to 49 days (Beck et al., 1993). 
However, when implanted into calvarial defects of the primate 
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Papio ursinus, hTGF-β1 promotes histologically and 
histomorphometrically limited chondro-osteogenesis and confined 
only to defect margins as evaluated on day 30 post implantation 
(Ripamonti et al., 1996c). 
 
 TGF-β1 also plays important roles during injury. Upon platelet 
degranulation at the injury site, TGF-β1 is released into the 
surrounding tissue and a complex sequence of events that 
promote healing is then initiated. Systemic injection of TGF-β2 
leads to generalized increase in osteoblastic activity (Rosen et al., 
1994). Systemic administration of TGF-β2 also prevents impaired 
bone formation and osteopenia induced by unloading in rats 
(Machwate et al., 1995).  Ripamonti et al. (1997) and Duneas et 
al. (1998) demonstrated that recombinant human and platelet-
derived TGF-β1 induces endochondral bone formation in 
heterotopic sites of the baboon (Papio ursinus). It was further 
demonstrated that hTGF-β1 interacts synergistically with hOP-1 to 
induce massive ossicles in the rectus abdominis of primates as 
evaluated by key parameters of bone formation on days 14 and 30 
postimplantation (Ripamonti et al., 1997). In 2000, Ripamonti and 
co-workers reported the heterotopic induction of endochondral 
bone formation by hTGF-β2 in the baboon (Papio ursinus) 
(Ripamonti et al., 2000a). They showed that hTGF-β2 induces 
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endochondral bone formation 30 days postimplantation in 
heterotopic intramuscular sites using insoluble collagenous bone 
matrix as well as sintered porous hydroxyapatite as carriers.  
 
In rodents however, TGF-β1 induces only granulation tissue with 
potentially marked fibrosis (Roberts et al., 1986; Shinozaki et al., 
1997). The finding that TGF-β1 is an inducer of endochondral 
bone formation in the primate raises important questions about the 
specificity and possible redundancy of proteins involved in bone 
formation and the evolutionary conservation of related proteins 
from phylogenetically distinct species (Ripamonti et al., 1997; 
Duneas et al., 1998; Ripamonti et al., 2000a). TGF-β1 however, 
has been reported to show limited bone induction in orthotopic 
sites of the baboon (Ripamonti et al., 1996c) suggesting that the 
bone inductive activity may be site and tissue specific (Ripamonti 
et al., 1997; Duneas et al., 1998; Ripamonti, 2000; Ripamonti et 
al., 2001). 
 
TGF-βs regulate a variety of osteoblast activities related to bone 
formation (Centrella et al., 1994). TGF-β2 functions as a local 
positive regulator of bone remodelling. Alterations in TGF-β2 by 
bone cells or in their responsiveness to TGF-β2 may contribute to 
the pathogenesis of metabolic bone disease (Erdebacher and 
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Derynck, 1996). TGF-βs also induce matrix protein synthesis in 
most tissues, more especially in bone. TGF-β isoforms have also 
been reported to enhance collagen production and collagen 
mRNA levels (Raghu et al., 1989). Fine et al. (1990) further 
investigated the effect of TGF-βs on collagen and reported that 
TGF-β isoforms increase the amount of collagen type I mRNA in 
human embryonic and lung fibroblasts. Further more, TGF-β 
isoforms increases the proliferative effect of epidermal growth 
factor (Fine et al., 1990).  
 
To date, TGF-βs, naturally-derived or recombinantly produced, fail 
to induce bone formation in rodents, showing instead a 
fibrovascular response (Roberts et al., 1986; Sampath et al., 
1987; Hammonds et al., 1991). Studies were performed in the 
subcutaneous space of rodents that confirmed that the heterotopic 
implantation of TGF-β1 and -2 combined with insoluble 
collagenous bone matrix or in conjunction with hydroxyapatite 
granular carriers, results in the induction of a fibrogenic response 
without any sign of cartilage or bone formation (Roberts et al., 
1986; Sampath et al., 1987; Hammonds et al., 1991; Shinozaki et 
al., 1997; Matsaba et al., 2001). Furthermore, it was demonstrated 
that when used in subcutaneous sites, TGF-βs 1 and -2 have 
been implicated in the genesis of cutaneous scarring due to 
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increased monocyte and macrophage infiltration and fibronectin 
and collagen types I and III deposition (Shah et al., 1995).  
 
However, in marked contrast to studies in rodents, TGF-βs-1 and -
2 induce vigorous endochondral bone formation in heterotopic 
sites of adult non-human primates (Ripamonti et al., 1997; Duneas 
et al., 1998; Ripamonti et al., 2000; Ripamonti et al., 2001). 
Ripamonti et al. (2000a) showed for the first time that hTGF-β2 
induces endochondral bone formation in heterotopic sites in adult 
baboons (Papio ursinus). The same study also demonstrated that 
TGF-β2 does not require only the insoluble collagenous bone 
matrix as carrier, since bone was initiated even when TGF-β2 was 
combined with sintered porous hydroxyapatites.  One important 
feature about TGF-βs is that the bone inductive activity in primates 
is site specific, with extensive endochondral bone induction in 
heterotopic sites but limited in orthotopic sites (Ripamonti et al., 
1996c; Duneas et al., 1998; Ripamonti et al., 2000; Ripamonti et 
al., 2001). The site and tissue specificity of bone induction by 
hTGF-β2 is not carrier related since equal results were obtained 
when sintered hydroxyapatites were used as carrier and implanted 
in orthotopic and heterotopic sites (Ripamonti et al., 2000). 
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1.10 BMPs/OPs and bone formation 
Naturally-derived BMPs/OPs were the first proteins to be tested 
applying the bone induction principle for the repair of bony defects 
in primate models including humans. In vivo studies of BMPs/OPs 
have made it possible to extend the knowledge of their 
morphogenetic potential from rodents to primates. Studies with 
primates are a prerequisite for the exploration of potential 
therapeutic applications for the regeneration of bone in man. The 
first experiments in humans were reported by Johnson and co-
workers, (1988). Upon the treatment of refractory tibial and 
femoral non-unions using various doses of naturally-derived 
BMPs/OPs, results showed union with BMPs/OPs 
supplementation in patients who had undergone unsuccessful 
multiple surgical grafting attempts (Johnson et al., 1988). In very 
recent experiments, naturally-derived BMPs/OPs have been 
implanted in craniofacial defects in man and the biopsy specimens 
from the operated sites examined 90 days after BMPs/OPs 
implantation. The results showed bone formation by induction 
(Ferretti and Ripamonti, 2002). 
 
The efficacy of naturally-derived BMPs delivered by both 
hydroxyapatites and collagenous substrata was demonstrated in 
the calvarial model of the adult baboon (Papio ursinus) and 
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heterotopically in the rectus abdominis by Ripamonti et al. 
(1992c); Ripamonti et al. (1993a); Ripamonti et al. (1993b); 
Ripamonti et al. (2001). Naturally derived BMP/OP fractions were 
shown to completely regenerate calvarial defects in adult baboons 
90 days post implantation (Ripamonti et al. 1992a; Ripamonti et 
al., 1993a). In 1994, Ripamonti et al. reported that naturally-
derived BMPs/OPs also play important roles in regenerating 
periodontal ligament, cementum and alveolar bone in surgically 
created periodontal defects in Papio ursinus (Ripamonti et al., 
1994). High doses of recombinant human OP-1 (hOP-1), when 
used with collagenous matrix as carrier, induces massive bone 
differentiation 30 days after implantation in calvarial defects 
(Ripamonti and Reddi, 1995; Ripamonti et al., 1996b). In addition, 
the pleiotropic function of BMPs/OPs has been shown by OP-1, 
BMP-2 and BMP-4 inducing also dentinogenesis (Rutherford et 
al., 1993; Nakashima et al., 1994).  
 
Osteogenic protein-1 (OP-1), also known as BMP-7, has been 
evaluated extensively in preclinical studies in critical size defects 
in rabbits, canine, sheep, and non-human primate models (Cook 
et al., 1994a; Cook et al., 1994b; Cook et al., 1995; Cook and 
Rueger, 1996; Ripamonti et al., 1996a; Ripamonti et al., 1997, 
Ripamonti et al., 2000b; Grauer et al., 2001). In each of the above 
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studies, hOP-1 was associated with a high degree of success, 
comparable in frequency and completeness of repair with that 
seen with bone autografts. More importantly, all new bone induced 
by osteogenic molecules, including hOP-1, is the same as the 
autogenous bone, and this bone continues to remodel in the same 
manner as is normal for the particular skeletal site and its 
biomechanical environment (Friedlaender et al., 2001).  
 
Takahashi et al. (1999) reported the use of porous hydroxyapatite 
graft containing human bone morphogenic protein-2 (hBMP-2) for 
cervical fusion in a caprine model. Their results showed that the 
addition of hBMP-2 to a porous hydroxyapatite graft enhances the 
rate of anterior cervical fusion. hBMP-2 has also been reported to 
enhance tendon healing in dogs (Rodeo et al., 1999). Their results 
showed accelerated healing in the sites where hBMP-2 was 
administered. Friedlaender et al. (2001) reported the safety and 
efficacy of hOP-1 in the treatment of tibial nonunions. They 
concluded that hOP-1, implanted with insoluble collagenous 
matrix as carrier, is a safe and effective treatment for tibial 
nonunions in clinical contexts. Moreover, their study provided 
clinical and radiographic results comparable with those achieved 
with bone autograft, without donor site morbidity (Friedlaender et 
al. 2001).  hBMP-2 has also been shown to play critical roles in 
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the healing of rat segmental femoral defects (Lee et al., 1994) and 
sheep segmental osteoperiosteal femoral defects (Gerhart et al., 
1993).  
 
 
In a rabbit ulna defect model, hOP-1 delivered by collagenous 
matrix was used to treat 1.5-cm segmental osteoperiosteal defects 
as evaluated 8 weeks after treatment (Cook et al., 1994). In an 
equivalent 8 week model, 2 cm rabbit ulna defects were treated 
with different doses of hBMP-2 delivered by D, L-lactide-co-
glycoside as carrier and there was a dose dependent response in 
bone regeneration. The newly formed bone was biomechanically 
of comparable strength with unoperated control ulnae (Bostrom et 
al., 1996).  
 
In African green monkeys, hOP-1 delivered by collagenous matrix 
as carrier was used to treat surgically created 2 cm 
osteoperiosteal defects in the distal tibiae and the ulnae. 
Radiographic and histologic evaluation at 20 weeks revealed that 
all hOP-1 treated sites underwent new bone formation (Cook et 
al., 1995). In a canine posterior segmental spinal fusion model, 
treatment with hBMP-2 delivered by D, L-lactide-co- glycolide 
resulted in equivalent spinal fusion rates as determined by 
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biomechanical testing when compared with autogenous grafts. 
The accumulated data from the above mentioned experiments 
and others have made it possible for both hOP-1 and hBMP-2 to 
proceed into the next step of clinical trials for both orthopedic and 
craniofacial applications. At the time of writing this thesis, the 
Food and Drug Administration (FDA) had not as yet approved 
hOP-1 for human orthopedic use. Yet, hOP-1 has been cleared in 
Europe and also in Australia. There are still challenges and more 
studies that need to be carried out to explore insights to the 
mechanistic events that take place in the regeneration and 
engineering of bone which may help to approach therapeutic 
tissue regeneration in molecular terms.  
 
1.11 Synergy between TGF-βs and BMPs/OPs  
Synergistic interactions amongst different classes of growth 
factors and morphogens could be a general principle deployed in 
embryonic development and in postnatal life as shown by 
experiments using different subclasses of growth factors and 
morphogens (Rameshwar et al., 1977; Ripamonti et al., 1997; 
Duneas et al., 1998; Sekiya et al., 1999).  
 
Previous studies have shown that TGF-βs when applied singly fail 
to induce bone formation in rodents (Roberts et al., 1986; 
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Sampath et al., 1987; Hammonds et al., 1991). Demonstration of 
therapeutic mosaicism in tissue engineering requires ample 
testing of doses and ratios of recombinant morphogen 
combinations (Ripamonti et al., 2000). It has been demonstrated 
that hOP-1 and recombinantly produced and platelet derived TGF-
β1 interact synergistically to architecturally configure large 
ossicles both heterotopically in the rectus abdominis and 
orthotopically in calvarial defects of adult primates (Ripamonti et 
al., 1997; Duneas et al., 1998).  
 
Ripamonti et al. (1997) and Duneas et al. (1998) showed that 
addition of comparatively low amounts of hTGF-β1 and pTGF-β1, 
respectively to hOP-1 resulted in synergistically increased 
parameters of bone formation 30 and 90 days post implantation in 
calvarial defects and heterotopically in the rectus abdominis. 
Ripamonti et al. (1997) reported that addition of hTGF-β1 to hOP-
1 led to a synergistic induction of bone formation 15 days post 
implantation in the adult primate. The binary applications resulted 
in the morphogenesis of cartilage highly reminiscent of de novo 
embryonic growth plates, indicating that the memory of 
developmental events in the embryo can be re-deployed post-
natally by the application of synergistic molecular combinations 
(Ripamonti et al., 1997).  
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The addition of TGF-β to hOP-1 influences tissue induction, 
directing development of events towards a more chondrogenic 
phenotype. Si et al. (1998) reported a synergistic interaction 
between TGF-β and BMP-2 in a hydroxyapatite bovine bone 
implanted heterotopically in mice. Matsaba et al. (2001) reported 
that TGF-β1, which singly does not induce bone formation in 
rodents, synergizes with hOP-1 to induce endochondral bone 
formation in rats as well as increasing the level of alkaline 
phosphatase and calcium temporally and dose dependently.  
 
Angiogenesis is a prerequisite for bone formation and it is a critical 
morphogenetic event invading the cartilage anlage to initiate 
osteogenesis (Foidart and Reddi, 1980; Reddi and Kuettner, 
1998). Enhanced vascularisation may hence be part of the 
mechanism whereby hOP-1 and TGF-β1 synergise in heterotopic 
bone induction. Ramoshebi and Ripamonti (2000), reported that in 
the chorioallantoic membrane (CAM) assay, hOP-1 is singly 
angiogenic and that this angiogenic activity is synergistically 
enhanced by the simultaneous application of pTGF-β1 resulting in 
a highly intense overall angiogenic response. These results further 
indicated an additional instance of a positive interaction between 
OP-1 and TGF-β1.  
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Bentz et al. (1989; 1991) reported in rodent experiments that the 
combination of naturally-derived BMP fractions (BMP-2 and -3) 
with bovine bone-derived TGF-β2 increased the ratio of cartilage 
to bone. Ogawa et al. (1992) also reported the enhancement of 
bone formation caused by the interaction of TGF-βs with naturally-
derived fractions containing BMPs 2 and -3. Their results 
demonstrated that implants containing combinations of naturally 
sourced TGF-β2 and BMP fractions resulted in increased 
chondrogenesis when compared to BMPs/OPs  alone in rodents. 
The results were dose dependent for TGF-β2 and increases in 
cartilage were noted at higher concentrations of the morphogen. 
The combination of the morphogens also increased alkaline 
phosphatase activity 8 fold when compared to BMP alone.  
 
In 1993, Kibblewhite and colleagues reported what may be a form 
of indirect synergy between BMPs and TGF-β1 in a rabbit 
craniofacial on lay model (Kibblewhite et al., 1993). The results 
showed that when TGF-β1 is added to demineralised bone matrix, 
it induces significantly higher amounts of bone and greater 
resorption of the implanted matrix when compared to 
demineralised bone matrix alone (Kibblewhite et al,. 1993). The 
authors' results demonstrate the potential of TGF-β1 in 
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accelerating osteoinduction. The reported TGF-β1 inductive 
behavior could have been influenced by the BMPs/OPs present in 
the demineralised bone matrix. 
 
Cunningham et al. (1992) also investigated synergy between 
BMPs/OPs  and TGF-βs. The authors suggested that BMPs/OPs 
may have early effects in bone induction by stimulating the 
chemotaxis of monocytes to the area. Once attracted, the 
monocytes are stimulated to produce chemotactic and mitogenic 
cytokines and growth factors including TGF-βs as shown by 
Northern blot analyses. Basic FGF (bFGF) has also been reported 
to accelerate actin expression in animal hemisphere cells when 
combined with TGF-β1  (Kimelman and Kirschner,1987). Synergy 
between bFGF and TGF-β1 has also been reported by 
Ramoshebi and Ripamonti (2000) in the CAM assay.  
 
There may be several mechanisms by which TGF-β synergizes 
with BMPs/OPs. As suggested previously for a combination of 
bovine-derived TGF-β2 and BMP fractions (Bentz et al., 1989; 
1991) TGF-β may act as a chemotactic and mitogenic factor for 
responding precursor cells for subsequent induction by 
BMPs/OPs. Also, possibly by simultaneous shift and redistribution 
in receptor binding profiles for TGF-β1 which are regulated by 
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hOP-1 (Centrella et al., 1995). Mundy (1995) suggested that while 
BMPs/OPs act at an earlier control point in the osteoblast lineage, 
TGF-β may regulate the latter steps in the bone and cartilage 
lineages. 
 
1.12 Other growth factors  
Advances in molecular cloning techniques have resulted in the 
expression of additional gene-related products of the BMP and 
TGF-β families. These include the CDMPs (Chang et al., 1994), 
GDFs (Lee, 1990; Jones et al., 1992; Mcpherron and Lee, 1993), 
the recombinant drosophila gene products decapentaplegic (dpp) 
and 60 A, vegetal-1 gene products of Xenopus laevis, MIS (Cate 
et al., 1986) and the hormones activins and inhibins (Mason et al., 
1985; Schwall et al., 1988; Cate et al., 1986; Padgett et al., 1987; 
Weeks and Melton, 1987; Lyons et al., 1989; Ripamonti and 
Vukicevic, 1995). Importantly, it was reported that the recombinant 
drosophila genes, dpp and 60A are inducers of endochondral 
bone formation in mammals (Sampath et al., 1993).   
 
It has also been reported that CDMP-1 and -2 are most closely 
related to BMP-5, -6, and -7 (OP-1) (Chang et al., 1994). In 
contrast to the other members of the BMP/OP family, expression 
of CDMP-1 and -2 is predominantly in the cartilaginous tissue, 
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hence the name, and particularly in condensing mesenchyme of 
developing limbs (Chang et al., 1994). The equivalent of CDMP-1 
in the mouse is GDF-5 and is linked to a mouse disorder 
characterized by a distinct shortening of the limbs without other 
tissue abnormalities, a mutation called brachypodism, suggesting 
that GDF-5 may be required for proper development of the limbs 
(Storm et al., 1994). The types of mutations observed in 
brachypodism mice were found to be effective null mutations for 
the gene encoding GDF-5/CDMP-1. Hotten et al. (1996) showed 
that hGDF-5 is capable of inducing chondrogenesis in vivo and in 
vitro in rat limb bud cells. Moreover, hGDF-5 has been shown to 
stimulate mesenchyme aggregation and chondrogenesis in rat 
limb bud cells in vitro, and also partially purified hGDF-5 induces 
cartilage and bone formation in muscular tissues of rodents in vivo 
(Hotten et al., 1996). GDF-10, a new member of the BMP family 
highly related to BMP-3, is strongly expressed in neonatal and 
adult calvariae, with lower expression in the femur, which is of 
endochondral origin unlike the calvaria which is of 
intramembranous origin (Cunningham et al., 1995). This 
observation suggests a site-specific regulatory role of different 
TGF-ß family members in various sites of the skeleton and 
underscores the therapeutic importance of site targeting with 
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exogenous applications of specific morphogens (Ripamonti et al., 
1997; 1998; Ripamonti and Duneas, 1998). 
 
Another group of growth factors, fibroblast growth factors (FGFs) 
have also been identified (Mundy, 1996; Reardon et al., 1994; 
Rousseau et al., 1994). The role of FGF and other growth factors 
in the regulation of angiogenesis in vivo has been well 
documented (Schreiber et al., 1986; Hayek et al., 1987; Sprugel et 
al., 1987; Cao et al., 1996; Fajardo et al., 1996). Other major bone 
cell mitogens whose receptors are frequently expressed in bone 
cells are platelet-derived growth factors (PDGFs) (Graves et al., 
1984).  
 
1.13 Carriers for bone formation 
Several carriers for bone formation have been investigated 
indicating that the carrier is critical for bone induction to occur. 
BMP-induced chondro-osteogenesis in heterotopic tissues was 
originally discovered by Urist (1965) upon implantation of DBM. 
One interesting aspect of BMP/OP-induced chondro-osteogenesis 
is that, to induce in vivo cartilage or bone formation, purified or 
recombinant BMPs/OPs require a carrier to act as a delivery 
system (Reddi, 1994a; Ripamonti and Duneas, 1996; Reddi, 
1994b; Ripamonti and Duneas 1998). The most widely used 
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carrier of BMPs/OPs is the insoluble collagenous bone matrix, 
which is the demineralised guanidinium extracted and inactive 
residue of the bone matrix. The osteoinductive nature of the 
demineralised bone matrix can be abolished by dissociative 
extraction resulting in two components: a soluble protein extract 
and an insoluble residue, which is the insoluble collagenous bone 
matrix (ICBM) (Sampath and Reddi, 1981). Reconstitution of the 
two components restores the osteoinductive activity. Sampath and 
Reddi, (1981) also showed that the factors responsible for 
osteoinductivity reside in the solubilised component and when 
reconstituted with an appropriate carrier, the osteoinductivity can 
be restored. This operational reconstitution was a hallmark in the 
field of bone induction since it allowed the identification of the 
proteins responsible for the osteoinductive activity as well as the 
focusing on carrier matrices as delivery systems.  
 
Itoh et al. (2000) investigated the biocompatibility and 
osteoconductivity of a novel hydroxyapatite/collagen (HAP/Col) 
composite biomaterial as well as its ability to act as a BMP/OP 
carrier. The authors reported that based on their findings, 
HAP/Col-composite has a high osteoconductive activity and is 
also able to induce bone remodelling. Furthermore they suggested 
that HAP/Col-composite has characteristics similar to natural bone 
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because it was able to induce the development of osteogenic cells 
and bone remodelling units. In cases where the HAP/Col-implants 
are grafted at sites where weight bearing is needed from the early 
postoperative days, treatment with hBMP-2 at a specific dose is 
useful to promote callus formation and to shorten the time needed 
for bone union (Itoh et al., 2000). 
 
BMPs/OPs, when reconstituted with ICBM, induce endochondral 
bone formation. Moreover, Sasano et al. (1993) showed that, 
other carriers such as a fibrous collagen membrane, when used 
with BMPs/OPs can induce direct bone formation independent of 
the cartilage phase. Kuboki et al. (1995) also showed that 
BMPs/OPs singly induce direct, i.e., intramembranous 
osteogenesis when porous particles of hydroxyapatite are used as 
carrier, while on the other hand, fibre glass membranes, when 
used as a carrier only induces chondrogenesis. The authors 
concluded that vasculature is the crucial factor that determines 
osteogenesis or chondrogenesis. Kuboki et al. (1998) reported 
that fibrous collagen membrane carrier does not only induce bone, 
but also regenerates cementum and periodontal defects in the cat 
canine and monkey molar, respectively. Miki et al. (2000) reported 
complete regeneration of bone with bone marrow four weeks after 
implantation of freeze dried poly glycolic acid-co-lactic acid 
 72
(PGLA) with hBMP-2 in rodents. The authors suggested that the 
FD-PGLA/HA/hBMP-2 composite could also be an optimum bone 
substitute with osteoinductive potential and could function as an 
alternative bone graft material for autogenous bone in humans. 
 
Previous studies revealed that there are cartilage-directing 
carriers such as fibrous glass membranes (Kuboki et al., 1995) 
and bone-directing carriers such as porous particles of 
hydroxyapatite and titanium mesh (Kuboki et al., 1998). It has also 
been shown that porous hydroxyapatites acted as ideal delivery 
systems for BMPs/OPs, providing evidence that the osteogenic 
activity of BMPs/OPs could be restored and delivered by an 
insoluble substratum other than the collagenous matrix (Ripamonti 
et al., 1992a; Ripamonti et al., 1992c and Ripamonti et al., 1993b). 
Ripamonti and co-authors have shown in a number of 
experiments that the implantation of specific porous 
hydroxyapatites in the rectus abdominis of primates resulted in the 
morphogenesis of bone 60 and 90 days after implantation even 
without the exogenous application of BMPs/OPs (Ripamonti, 
1990; Ripamonti et al., 1991b; Ripamonti et al., 1993b; Ripamonti, 
1996). Bone formation may be the result of adsorption of 
endogenously produced or circulating BMPs/OPs onto the 
substratum and induction of bone as a secondary response 
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(Ripamonti et al., 1991b; Ripamonti et al., 1993a; Ripamonti et al., 
1993b;  Ripamonti et al., 1999).  
 
As previously reported, spontaneous bone formation occurs within 
the concavities of hydroxyapatite (Ripamonti et al., 1999. 
Immunolocalisation patterns of BMP-3 and OP-1 were observed in 
the concavities at the hydroxyapatite interface with the invading 
fibrovascular tissue (Ripamonti et al., 1999; Ripamonti, 2000c). 
The question remains:  
 
Are BMPs/OPs present within the concavities locally produced to 
initiate bone formation within the concavities of the substratum, or 
rather secreted onto the hydroxyapatite by invading capillaries 
with associated mesenchymal cells and later initiating bone 
formation as a secondary response? 
 
 
It is against this background that the present study was conducted 
to investigate the two possibilities. 
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2.0 AIM 
To investigate whether BMPs/OPs present within the concavities 
are locally produced to initiate bone formation within the 
concavities of the substratum, or rather secreted onto the 
hydroxyapatite by invading capillaries with associated 
mesenchymal cells and later initiating bone formation as a 
secondary response. 
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3.0  MATERIALS AND METHODS 
3.1 Selection of animals 
 
Six clinically healthy adult Chacma baboons (Papio ursinus) were 
selected from the primate colony of the University of the 
Witwatersrand, Johannesburg. Criteria for selection were normal 
hematological and biochemical profiles (Melton and Melton, 1982) 
and skeletal maturity, confirmed by radiographic evidence of 
closure of the distal epiphyseal plate of the radius and ulna. 
Following standard quarantine procedures, the animals were 
housed individually in suspended wire-mesh cages in the primate 
unit of the Central Animal Service of the University. Animals were 
kept under slight negative pressure (-25 kPa) with controlled 
ventilation, at 22oC and humidity at ±40%, and controlled 
photoperiod (lights on 06h00 to 18h00). The diet of the baboons 
consisted of a balanced protein-fat-carbohydrate diet with vitamins 
(thiamine, riboflavin and nicotinic acid) and mineral supplements 
(Calcium: Phosphate (Ca:P) = 1.2:1), and a soft dietary intake of 
sweet potatoes, pumpkins and oranges mixed in a ratio of 3:1 with 
a protein-vitamin-mineral dietary supplement (Dreyer and Du 
Bruyn, 1968). The baboons had access to tap water ad libitum. 
The research protocol was approved by the Animal Ethics 
Screening Committee of the University (AESC number: 00/106/5).  
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3.2  Biomaterials 
 
Four different types of substrate materials were prepared in the 
form of discs (20mm diameter X 3mm thickness) with a series of 
concavities on both planar surfaces (Figs. 1A and 1B). The discs, 
with specific geometries were constructed by the Council of 
Scientific and Industrial Research (CSIR), Materials and 
Technology group (MATTEK), Pretoria, South Africa.  In this study 
the term geometry refers to concavities of different dimensions, 
which act as microenvironment for induction of bone. 
 
 
3.3 Powders 
 
Four different types of powders containing hydroxyapatite (HA) 
were used for the uni-axially pressing of sample discs. The 
samples were in the form of discs of 3mm thickness and 20mm 
diameter. Pressing was done at 20 MPA in a piston and die 
arrangement (Fig. 2) using a polymeric pressing binder. The 
pistons that were used for pressing had embedded hemispheres 
of different diameters and depths on both planar surfaces.  
 
The resulting discs therefore had hemispherical indentations on 
the surfaces with the depth of half the diameter of the 
indentations.  The same HA starting powder that was used in type 
2 biomaterials was also used in types 3 and 4. The major 
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differences between the implants were particle size and 
distribution of the starting powders. as opposed to a highly 
crystalline, coarsened (>1 microns) hydroxyapatite powder (Type 
2), or a fine distribution (<100 microns) of TCP in hydroxyapatite 
matrix (Type 3) as opposed to discreet (100-300 microns) zones 
of TCP in hydroxyapatite matrix (Type 4) both produced from 
highly crystalline coarsened powders 
 
3.4 Preparation of biomaterials 
Phase pure HA with a calcium/phosphorus (Ca/P) molar ratio of 
1.67 was prepared by a solid-state reaction between Merck tri-
calcium phosphate (TCP) [Ca3 (PO4 )2 ] and Univar calcium 
hydroxide [Ca(OH)2] according to the chemical reaction: 
3Ca3(PO4)2 + Ca(OH)2 = Ca10(PO4)6(OH)2 
The specification of the foodstuff grade TCP was: Cl (chloride) 
<0.1%, F (fluoride) <0.005%, (SO4) sulphate <0.5%, 
As<0.0002%, Fe (iron) <0.04% and the total of all heavy metals 
<0.003%. Less than 0.1% was insoluble in hydrochloric acid. The 
calcium hydroxide had a stated assay of 95-100% with carbonate 
<5%. The stated As contents was below 0.0003%, with copper 
(Cu) <0.001%, Fe< 0.1% and the total of all heavy metals 
<0.002%.  
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All samples were air-fired. The elements mentioned were in 
accordance to ASTM Standard F1185-88 which is for ceramic 
hydroxyapatite intended for surgical implants with a total heavy 
metal limit as 50ppm. The stated purities of the chemicals are 
within these limits. Indivisual samples were not analysed, but the 
material from which the samples were made, was analysed. 
   
Aqueous suspensions of the starting materials (HA) were mixed in 
a Silverson High shear high-speed mixer for 15 minutes and then 
gelled with a suitable gelling agent (Rohm and Haas Duramax D-
3007) to prevent separation during drying. The material was dried 
at 120oC for 12 hours. The dry-soft cake was crushed and 
screened below 300 micron. The loosely packed powder was 
reacted in covered alumina crucibles at 1000o C for 18 hours to 
yield hydroxyapatite as verified by Scanning Electron Microscopy 
(SEM), X-Ray powder Diffraction (XRD) and Fourier Transform 
Infra-Red Spectroscopy (FTIR) and it was ball-milled to a powder 
with a median particle size of approximately 1 micron (Thomas et 
al., 1999; Richter et al., 1999). 
 
The discs were pressed from powder in the DIE system using two 
pistons with embedded steel balls on their faces (Fig. 2) - one 
piston from each side. Since the balls pressed into the powder 
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only half way (being halfway into the steel piston) the depths of 
the concavities were half the diameter of the concavities.  One 
side of the disc had 25 concavities of the same diameter and the 
other side had 69 (smaller) concavities of the same diameter, 
different from the previous side (Figure 1). The size of the 
concavities was varied on both sites of the discs to determine the 
range of diameters suitable for induction. The diameters and 
depths of the different concavities will be discussed in detail in the 
following subsections of the implanted different biomaterials  
 
The final preparation of the samples was the sintering step at 
1020 oC for 1 hour using a ramp rate of 1.5 oC/minute. This was 
also a thorough sterilization treatment process, which resulted in 
any remnants of any organic material, living or dead, being 
vaporized. From the furnace the samples were immediately 
transferred in closed containers to a laminar flow cabinet where 
filtered air flowed over it. The samples were then transferred into 
envelopes of Sterilpeel that were immediately sealed in a thermal 
sealer - all the time untouched by hand.  They were taken to the 
Bone Research Laboratory where they were autoclaved at 121oC 
for 20 minutes. On the microstructural level, the substrata 
presented a surface with high open microporosity and with specific 
surface area in excess of 1.5m2 /g. 
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3.5 Type 1 samples 
A commercially available hydroxyapatite powder (from Plasma 
Biotal, batch P120) which consisted of relatively fine particles (1 
micron) of hydroxyapatite was mixed with a pressing binder for 
pressing Type 1 samples.  
 
The samples were sintered to yield discs of 20mm in diameter and 
3mm thick. One side of the disk had concavities of 1.8 mm in 
diameter and a depth of 0.9mm. The other side had concavities of 
0.9 mm diameter and 0.45mm depth. These samples had a 
microporosity (bulk material) of 39%. Type 1 samples were the 
only samples pressed using a commercial powder. 
 
 
 
3.6 Type 2 Samples 
Hydroxyapatite powder (HAOM 21) was pressed similar to the 
Type 1 samples.  
The starting powder consisted of a highly crystalline, coarsened 
(>1 microns) hydroxyapatite powder. The discs had a 
microporosity (bulk material) of 40%. Concavities had diameters of 
1.9mm on one side with a depth of 0.8mm, and 1.0mm on the 
other side with a depth of 0.5mm.  
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3.7       Type 3 Samples 
The same hydroxyapatite starting powder that was used in type 2 
samples was mixed at the micron level with a fine distribution 
(<100 microns) of tri-calcium phosphate powder to yield a 
homogeneous powder consisting of 37 mass percent TCP and 63 
mass percent HA. The powder was pressed into discs having 
hemispherically indented surfaces. The concavities had a 
diameter of 1.9 mm on one side with a depth of 0.8mm and 
1.0mm on the other side with a depth of 0.5mm. The samples had 
a microporosity (bulk material) of 38%. 
 
3.8 Type 4 Samples 
The same HA starting powder that was used in type 2 and 3 was 
used with discreet (100-300 microns) zones of TCP both produced 
from highly crystalline coarsened powders. Samples consisted of 
a 37 mass percentage TCP mixture with 63 mass percent HA. 
Type 4 samples therefore differed from the Type 3 samples in that 
large agglomerates of TCP and of HA were separately formed 
prior to pressing. These agglomerates were then mixed 
homogeneously and then pressed into discs that were sintered. 
The microporosity (bulk material) of type 4 samples was 37%. The 
diameters of the concavities were 1.9mm and 1.0mm while the 
depth was 0.8mm and 0.5mm respectively. 
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Figure 1A: Photomicrograph of a hydroxyapatite disc with 
concavities on both planar surfaces. 
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 Figure 1B: 
 
Photomicrograph of a hydroxyapatite disc showing concavities  
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Figure 2.  Die system used to create concavities on the samples 
 
 
 
 
 
 
 
 
 
 
 
 
 85
3.9 Implantation Protocol 
 
Before implantation in the baboon, the samples were sterilized in 
an autoclave at 121o C on dry cycle for 20 minutes. The 
heterotopic model of tissue morphogenesis by osteoinductive and 
osteoconductive biomaterials in the adult baboon has been 
described in detail (Ripamonti, 1992; Ripamonti et al., 1992a; 
Ripamonti et al., 1993b; Ripamonti, 1996). In four animals, a total 
of 64 discs were implanted bilaterally in intramuscular pouches to 
be harvested on day 30 and 90. Four discs were implanted per 
pouch created in the rectus abdominis                                                                 
muscle, 16 implants per animal, as shown in Fig. 3. 180 days 
post-implantation in the additional two animals, only Types 2 and 
4 were implanted, 8 implants per animal. The total number of 
implants for the study was 80. All discs were implanted in the 
same relative position with the larger concavities facing ventrally.  
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Figure 3. Implantation protocol for the heterotopic model:  
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3.10 Tissue processing and analytical procedures 
Anaesthetized animals were euthanased with an intravenous 
overdose of sodium pentobarbitone, 2 animals on day 30, 2 
animals on day 90 and 2 animals on day 180. Implants were 
harvested, freed of adhered soft tissues and then subjected to 
histological and immunohistochemical analyses (Ripamonti et al., 
1999). For biochemical and Northern Blot analyses, the tissues 
grown on both planar surfaces and within the concavities of the 
substratum were peeled off the disc and pooled for each type of 
sample.  
 
3.11 Alkaline Phosphatase assay 
 
Refer to Appendix 1 for the list of reagents. 
 
3.11.1 Method:  
 
Harvested tissues were homogenised in 2 ml of homogenising 
buffer. After centrifugation the alkaline phosphatase activity of the 
supernatant was used as index of bone formation by induction 
(Reddi and Huggins, 1972; Ripamonti et al., 1997; Duneas et al., 
1998, Matsaba et al., 2002).  
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The supernatant was transferred into a new tube and used for the 
assay. One ml of substrate solution and 1 ml of buffer solution 
were added to clean test tubes which were then placed in a 37oC 
water bath to equilibrate temperature. Blanks were prepared by 
adding 2 ml of base solution to tubes containing substrate and 
buffer solutions. The sample assay was then added to all tubes 
and the reaction was left for 30 minutes after which it was stopped 
with 2 ml of the base solution.  
 
The alkaline phosphatase activity was detected by the 
appearance of a yellow coloured reaction that resulted from the 
enzymatic conversion of the substrate, para-nitrophenyl 
phosphate (PNPP) at pH 9.3. The absorbance of the samples was 
determined by spectrophotometer at 400 nm. Alkaline 
phosphatase was determined as units of activity per mg protein. 
One unit of alkaline phosphatase activity is defined as that which 
generates 1 µg of PNPP in 30 minutes at 37oC. This unit of activity 
was calculated based on the extinction coefficient () value of 
PNPP, which is 218.58. The amount of solubilised protein was 
determined by the Lowry assay (Lowry, 1951).  
 
 
 89
 
3.12 Protein Lowry Assay 
 
Refer to Appendix 2 for reagents  
 
3.12.1 Method: 
 
Standard solutions were prepared with appropriate volumes (20, 
40, 60 and 80 l) of the BSA stock. To standards and sample 
tubes, distilled water was added to give a final volume of 400 µl. 
Blanks were prepared with distilled water without sample assay. 
To all tubes, 2 ml of copper reagent were added and the reaction 
was allowed to proceed for 30 minutes after which 200 µl of 
phenol reagent was added and contents vortexed. The reaction 
was allowed to proceed for another 30 minutes and the 
absorbance of the samples was determined at 750 nm by using 
standard values to obtain a standard curve, and the protein in the 
sample read from the curve. 
 
3.13 Histology 
Harvested tissues were fixed in 10% formalin (pH 7.4) and 
demineralised in formic acid-hydrochloric acid solution. After 
dehydrating in ascending grades of ethanol, tissues were 
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impregnated with nitrocellulose, cleared in chloroform and 
impregnated with paraffin wax under vacuum and embedded in 
paraffin wax. Sections were cut at 4 m and stained using a 
modified Goldner's Trichome method outlined below (Ripamonti et 
al., 1997; Duneas et al., 1998; Ripamonti et al., 1999; Ripamonti, 
2000c; Ripamonti et al., 2000a).  
 
Refer to Appendix 3 for reagents 
 
3.13.1 Method (modified Goldner’s Trichome): 
 
The difference between the original Goldner’s stain and the 
modified method is the counterstaing. The original method 
counterstains with a green stain while the modified method 
counterstains with a blue stain so everything that is green 
representing mineralized bone in the original method will appear 
blue in the modified method. The blue stain representing 
mineralised bone was chosen for photographic purposes. Bone is 
differentiated from the dense connective tissue and any other 
tissue that make the blue stain by the fact that bone has 
osteocytes; this is a characteristic feature that all the other tissues 
in the study do not have. Morphologically, bone stains blue on 
decalcified sections (with modified Goldner’s Trichome) as matrix 
 91
with lacunae filled by osteocytic cells and often has osteoblastic 
cells facing the connective tissue matrix highly vascularised. 
 
Sections were stained in stable iron haematoxylin for 20 minutes, 
fuschin ponceau for 45 minutes, differentiated in Orange G for 20 
minutes then stained in methyl blue for 10 minutes. In between the 
stains, sections were washed in running tap water, differentiated 
in acid alcohol and immersed in 1% acetic acid. The sections were 
then dehydrated in series of alcohol and mounted with entellan 
(Merck, Germany). 
 
3.14 Immunolocalisation of TGF- family members 
Additional sections were cut at 5 µm, mounted on incubated 
silanized slides, and used for immunohistochemical staining of 
OP-1 and BMP-3 markers of bone formation.  
 
Refer to Appendix 4 for reagents 
3.14.1 Method: 
Pre-stained sections were rehydrated in series of ethanols and 
decolourised in 1% acid alcohol, washed in water and placed in 
buffer. Slides were then placed in hydrogen peroxide and rinsed 
again in buffer. Horse serum, primary antibody, and secondary 
antibody were added followed by 3, 3-diamino benzidine (DAB) 
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(Sigma-Aldrich, Germany) then rinsed in tap water. The control 
samples were prepared without the primary antibody, which was 
replaced by buffer. The control was run for all samples. The nuclei 
was stained with Carazzi’s Haematoxylin, dehydrated and 
mounted with entellan (Merk, Germany).  
 
3.14.2  Antibodies 
All antibodies were bought from Santa Cruz Biotechnology, Inc. 
Whitehead Scientific (Pty) LTD, Brackenfell, South Africa. 
 
OP-1: An affinity-purified goat polyclonal antibody raised against a 
peptide mapping at the amino terminus of the OP-1 of human 
origin. 
 
BMP-3: An affinity-purified goat polyclonal antibody raised against 
a peptide mapping at the amino terminus of the BMP-3 precursor 
of human origin. 
 
3.15 Northern Blot Analysis 
3.15.1  Preparation of total RNA 
Refer to Appendix 5 for reagents 
3.15.2 Method: 
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Pooled tissues harvested from the concavities weighing between 
100 and 200 mg from replicate specimens were used for Northern 
analyses. These tissues were peeled off the surface of the 
concavities. All glassware was baked at 250oC overnight and 
plastic ware autoclaved at 121oC for 20 minutes in the presence of 
0.1% DEPC (ICN Biochemicals Inc. OHIO). All solutions were 
prepared in deionised distilled water treated with DEPC. Sample 
tissues were snap-frozen in liquid nitrogen and stored at -70oC.  
 
Samples were crushed to a fine powder with a heat-sterilized 
mortar and pestle pre-cooled to -70oC. Crushed samples were 
homogenised on ice in Tri- Pure isolation reagent (Boehringer 
Mannheim Biochemicals), 1 ml per 100 mg of tissue, with an IKA 
Ultra-Turrax T025 tissue homogeniser at 20000 rpm (Janke and 
Kunkel, Staifen, Germany). Following homogenisation, samples 
were centrifuged at 4000 rpm in a Heraeus megafuge at room 
temperature for 10 minutes. The supernatant was aliquoted into 2 
ml Eppendorf tubes and the pellet was discarded. Chloroform (0.2 
ml/ 100 ml of the supernatant) was added and the tubes were 
shaken for 15 seconds and left at room temperature for 
15minutes, then centrifuged at 13000 rpm at 4oC for 20 minutes to 
separate the phases.  
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The upper layer that contained the RNA was transferred to a new 
tube and 0.5 ml of 100% isopropanol was added for 1ml of 
aqueous layer. The tubes were capped and inverted several times 
to mix, then incubated at room temperature for 15 minutes to allow 
the RNA to precipitate. The tubes were spun in a microfuge at 
13000 rpm at 4oC for 20 minutes to pelletise the RNA. The 
supernatant was discarded and the pellet was washed with 75% 
ethanol to reduce the salt concentration. The tubes were vortexed 
briefly until the pellet floated, and spun to settle the pellet. The 
ethanol was decanted and the pellets were dried for 5 minutes 
under vacuum. The pellets were resuspended in 30µl of lauryl 
sarcosine/EDTA solution.  
 
The concentration of the RNA was determined 
spectrophotometrically at 260 nm by employing an extinction 
coefficient of 1 representing a concentration of 40 µg/ml. The 
quality of the RNA was judged by the A260/A280 ratio of 
absorbance of the sample; the scrutiny of the quality of ribosomal 
RNA bands visualised on agarose gels and by the quality of 
gamma actin signals on Northern blots. 
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3.16 Formaldehyde Agarose Gel Electrophoresis 
 
Refer to Appendix 6 for reagents 
 
3.16.1  Method: 
A 2% stock agarose (electrophoresis grade) gel was made in 
0.1% DEPC treated water and autoclaved. The appropriate 
volume of the gel was melted in the microwave oven, mixed with a 
volume of concentrated electrophoresis buffer to give a 1x 
concentration in the final preparation and with formaldehyde to a 
final gel concentration of 1% agarose. 
 
3.17 Sample preparation and gel electrophoresis 
Refer to Appendix 7 for reagents 
 
3.17.1  Method 
 
Before electrophoresis, samples of RNA containing 5 and 20µg of 
RNA were denatured at 65oC in appropriate volumes of 
formamide, formaldehyde and 5X electrophoresis buffer. Samples 
were then mixed with gel loading buffer and electrophoresis was 
started at 5V/cm until the dye had reached 2/3 of the gel length. 
The gel was stained with ethidium bromide (500 ng/ml in 0.1M 
ammonium acetate) for 1 hour and then destained for 16 hours 
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with changes of DEPC treated water. The gel was then 
photographed on ultra violet illumination using a Polaroid camera. 
 
3.18 RNA transfer to membrane 
 
Refer to Appendix 8 for reagents 
 
3.18.1  Method: 
 
A 20X concentrate of SSC was prepared by adding 175.3g of 
NaCl and 88.2g of tri-sodium citrate to 1 litre of DEPC treated 
water, adjusting the pH to 7.0. The solution was sterilized by 
autoclaving at 121oC for 20 minutes. RNA was transferred to a 
nylon membrane (Hybond N+, Amersham) by capillary blotting 
using an apparatus specific for the purpose (Life Science 
Technologies, UK). The transfer was allowed to proceed for 48 
hours in the presence of 20X SSC as described (Sambrook et al., 
1989). The membrane was baked at 80oC under vacuum to effect 
the crosslinking of RNA to the membrane. 
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3.19 Probes and hybridization 
3.19.1 probes: 
Type II collagen: this is a 2.2 kb fragment of the gene, coding from 
amino acid 343 of the triple helix to 70 amino acids inside the C-
propeptide (Baldwin et al., 1989).  
Type IV collagen-alpha 2 cDNA: this is most of the collagenous 
domain (Hostikka and Trygvasson., 1988).  
 
OP-1 cDNA: comprises a 679 bp fragment harboured within 
pÖ320 (Helder et al., 1995) and covers amino acids 63 to 262 of 
the pro-region and the first 25 amino acids of the mature 
polypeptide.  
cDNA for TGF-ß1 (pRK5-ß1E): contains the unmodified wild type 
TGF-ß1 precursor (Derynck et al., 1985).  
 
cDNA BMP-3: contains a 1508 bp insert including the full coding 
region of hBMP-3 (Wozney et al., 1988).  
 
cDNAs for gamma actin and collagens were gifts of Professor de 
Wet, University of the Witwatersrand, Johannesburg. 
cDNA for OP-1 was a gift from Dr David Rueger, Stryker Biotech, 
Boston, MA, USA.  
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cDNA for BMP-3 was a gift from Professor A. Hari Reddi, formely 
at John Hopkins University, Maryland, USA.  
 
Type II collagen cDNA was a 2.2 kb fragment of the gene, coding 
from amino acid 343 of the triple helix to 70 amino acids inside the 
C-propeptide (Baldwin et al., 1989). 
 
cDNA for TGF-ß1: (pRK5-ß1E) contains the unmodified wild type 
TGF-ß1 precursor (Derrynck et al., 1985). cDNAs for OP-1 and 
TGF-ß1 were gifts from Professor S. Vukicevic, University of 
Zagreb, Croatia. 
 
3.20 Amplification of Constructs of E. coli 
Refer to appendix 9 for reagents 
 
3.20.1  Method: 
Escherichia coli strain XL1Blue, a gift from W. de Wet, department 
of Medical Biochemistry, University of the Witwatersrand, was 
used as a vector for transformation. An overnight culture was 
prepared in LB medium (0.5% bacto yeast, 1% NaCl, 1% 
bactotryptone (Life technologies, UK) in deionised water which 
was autoclaved at 121oC for 20 minutes on liquid cycle and cooled 
to room temperature. Bacteria were then grown for 16 hours on 
 99
LB-agar (Sigma Aldrich, Germany) plates. The bacteria were 
made competent by the CaCl2 method (Cohen et al., 1972).  
 
Briefly, a single bacterial colony was picked from the LB agar plate 
and inoculated into 10 ml of LB medium, incubated at 37oC with 
vigorous aeration overnight. One ml of the overnight incubation 
was transferred to 100 ml of LB medium in a 1 litre flask and 
incubated at 37oC with vigorous aeration until the OD600 was 
approximately 0.4. The cells were transferred to a sterile ice-cold 
50 ml falcon tube, cooled by placing on ice for 10 minutes after 
and were recovered by centrifugation at 4000 rpm for 5 minutes at 
4oC. The medium was decanted and the pellet was resuspended 
in 10 ml ice-cold 0.1 M CaCl2 by gentle shaking and stored on ice 
for 30 minutes. The cells were recovered by centrifugation again 
at 4000 rpm for 5 minutes at 4oC. The pellet was resuspended in 2 
ml of ice-cold CaCl2 (0.1 M) for each 50ml of original culture, 
mixed with glycerol (0.15 ml glycerol: 0.85 ml cells) snap-frozen in 
liquid nitrogen and stored at -70oC until use. 
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3.21 Transformation of E.coli 
 
Refer to Appendix 10 for reagents 
3.21.1  Method: 
Using a chilled sterile pipette tip, 200 µl of the bacterial 
suspension was transferred to a sterile Eppendorf tube. Super 
coiled plasmid DNA (100 ng) was added to the tube, mixed and 
stored on ice for 30 minutes. A control was made with competent 
bacteria that received no plasmid. The cells were transferred to a 
water bath at 42oC for 90 seconds, and back to ice for 2 minutes. 
LB medium (800 µl) was added to the mixture and incubated at 
37oC with gentle aeration for 45 minutes to allow the bacteria to 
express the antibiotic resistance marker encoded by the plasmid. 
100 µl of the transformed competent cells was transferred on to 
90 mm LB agar plates containing the appropriate antibiotic and, 
using a sterile bent glass rod, the transformed cells were spread 
over the surface of the agar plate. The plates were inverted and 
incubated at 37oC overnight. 
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3.22 Preparation of plasmid DNA 
 
Refer to Appendix 11 for reagents 
3.22.1  Method: 
A High Pure Plasmid Kit (Boehringer Mannheim) was used for this 
purpose. Plasmid DNA was isolated from E.coli (XL1 Blue) by 
lysing the bacterial cells according to the alkaline lysis method 
(Birnboim and Dolly, 1979). An overnight culture of transformed 
bacterial cells was grown in 4 ml of LB at 37oC. Cells were 
collected by centrifugation in the Heraeus megafuge. The cells 
were lysed and bacterial RNA was removed by the addition of 
RNAse A supplied with the kit. The lysate was neutralised and 
adjusted to high salt binding conditions after which chromosomal 
DNA was precipitated and the supernatant, which contained the 
plasmid was purified from the salts, proteins and other cellular 
impurities and eluted in 10 mM Tris-HCl buffer. 
 
3.23 Preparation of probe Labelled with 32P dCTP  
Refer to Appendix 12 for reagents 
3.23.1  Method: 
The vector DNA was treated with suitable restriction enzymes to 
cleave the inserts. Restriction digests of plasmid vectors and 
molecular weight markers were run on 1% agarose gel in TBE 
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buffer at 5 volts per centimetre. The DNA was visualised by 
ultraviolet (UV) transillumination of the gel.  
 
The inserts were identified according to molecular weight. The 
DNA concentration was then determined by spectrophotometric 
analysis of the sample absorbance at a wavelength of 260 nm, 
where an absorbance of 1 unit represents a DNA concentration of 
50µg/ml. DNA (25 ng) was labelled with alpha- 32P dCTP using a 
random prime labelling kit (DNA megaprime labelling kit RPN 
1606, Amersham Life Science). A DNA purification kit (QIAquick, 
White Head Scientific) was used to remove unincorporated label 
and the purified probe was used for hybridization. 
 
3.24 Hybridisation of probes and detection 
Refer to Appendix 13 for reagents 
3.24.1  Method 
Conical propylene tubes of 50 ml capacity were used for the 
hybridization procedure that was carried out in a hybridization 
oven (Hybaid Corporation, UK). The probe was mixed with 100 µl 
of sonicated fish sperm DNA (10 mg/ml) and boiled for 2 minutes 
to denature the DNA. A hybridization solution (QuikHYB, White 
Head Scientific) supplied commercially for this purpose was used 
to prehybridize membranes first at 37oC for 10 minutes, then at 
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68oC for 20 minutes. Probe was added and hybridization was 
allowed to continue for 2 hours at 68oC except for type IV collagen 
detection, which was carried out at 72oC because of the non-
specific binding of the probe to GC rich sequences of ribosomal 
RNA at lower temperatures.  
 
Membranes were washed twice for 15 minutes at room 
temperature with 150 ml of 2X SSC, 0.1% SDS, followed by 
another wash at 68oC with 0.1X SSC, 0.1% SDS. The blot for type 
IV collagen was washed at 72oC to achieve a higher stringency. 
Membranes were dried on blotting paper and covered with a 
Saran Wrap. Autoradiography was performed with Kodak Biomax 
MS film at -70oC for given time periods, ranging between 16 hours 
to 5 days. Films were developed and processed. 
 
3.25 Signal quantitation 
The signal intensity for each lane was quantitated by scanning 
densitometry (Gel Documentation and Analysis system, Syngene, 
U.K) and normalized against values obtained for the gamma actin 
signal. Values were adjusted to relative densitometric units and 
presented as percentages of gamma actin signals (Matsaba et al., 
2001; Ripamonti et al., 2000a). 
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3.26  Quantitative analyses 
The histological sections of 90 and 180 days were analyzed to 
quantitate the percentage area of the newly formed bone in 
relation to the total surface area of the concavity. The sections 
were analyzed under a research microscope (Provis X70, 
Olympus Optical Co. Japan) projected to a computer. The 
analysis was achieved with the support of a computer software 
(Flexible Image Processing System ® ver. 2.15, CSIR, South 
Africa) installed in a Pentium computer with a colour monitor 
(Ripamonti et al., 1996a, Ripamonti et al., 1997; Ramoshebi and 
Ripamonti, 2000). The area of bone in mm2 that had formed in the 
concavities was measured in relation to the total surface area of 
the concavity and presented in the form of percentage using a 
mathematical formular: 
 
% of bone=area of bone/total area of the concavityX100.  
 
3.27     mRNA analysis  
The signal intensity for each lane was quantitated by scanning 
densitometry (Gel Documentation and Analysis system, Syngene, 
U.K) and normalized against values obtained for the gamma actin 
signal. Values were adjusted to relative densitometric units and 
presented as percentages of gamma actin signals in the form of 
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bar graphs (Ripamonti et al., 2000a; Matsaba et al., 2001).  The 
signal intensities for the three different time periods were 
compared visually based on the percentage values obtained for 
the signal intensities and recorded in the form of a table as 
follows: +++ high expression, ++ moderate expression, + low 
expression, - no expression (Table 1). 
 
3.28     Statistical analysis 
The data were analyzed with the Graph Pad PrismTM version 2.0 
(San Diego USA). An Analysis of Variance procedure (ANOVA) 
was performed. Comparison of the mean values was obtained 
using the Bonferroni’s Multiple Comparison Test procedure on the 
dependent variables that were included in the analysis. The critical 
level of statistical significance chosen was P < 0.05. 
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4.0 RESULTS 
4.1 Characterisation: 
4.1.1SEM 
Figure 4A: A SEM image of the HA used for Type I sample, 
showing the microporosity 
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Figure 4B. A SEM image of the HA used as Type II sample, the 
same HA was used for type III and IV samples. The microporosity 
can be seen. 
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Figure 4C. A SEM image of the HA/TCP used as Type III sample, 
showing the microporosity 
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Figure 4 D: A SEM image of the HA/TCP used as Type IV 
showing the microporosity 
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Figure 5. 
4.1.2 XRD 
Specimens of the implant were subjected to XRD analysis on a 
Phillips PW 1830 generator operating at 45kV and 20 mA. Copper 
Kalpha1 radiation with a wavelength of 1,5406 A0  was used. The 
sample was scanned at a stepsize of 0,02 degrees  2-theta and 
step time of 1 second. Phase identification was done through 
comparison of the diffractogram with standard data from the 
ICDD. 
The results are shown below.  No significant quantity of any phase 
other than hydroxyapatite was noted. 
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A. XRD pattern of the Plasma Biotal material that was used as 
Type I material.  The pattern shows it to be single phase. 
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B. XRD of the HA material used as Type II showing it is single 
phase material.   This powder was also used as the HA 
component in Types III and IV samples. 
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Figure 5C. XRD spectrum for type III materials showing the 
presence of HA and TCP that made up the sample. 
 
 
 
 
 
 
HA/TCP
 Type
 3
 sample
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
1000025
27
29
31
33
35
37
39
41
43
45
2Theta
C o u n ts
HA/TCP
 
HA
 
TCP
 114
Figure 5D. XRD spectrum for type IV materials showing the 
presence of HA and TCP that made up the sample. 
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B. FTIR spectrum of the Type II HA material that was also used as 
the HA component in Types III and IV. The observed band at 3571 
cm-1  is indicative that the OH groups are intact. 
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C. FTIR spectrum of type II material. The lower spectrum is that of 
the material as used in the ceramics for types II, III and IV 
ceramics. The top spectrum is that of the material after it has been 
exposed to a temperature of 1 240C for 3 hours to ascertain its 
stability under these conditions. The spectra show that the 
material was essentially unchanged and would not readily 
degrade under the sintering conditions used in the present study. 
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D. The FTIR spectrum of the Type II material (previous page lower 
–figure 6 C) in comparison with that of the commercial Merck HA 
material (top figure 6C) and Friedrichsfeld HA material (previous 
page figure 6 C middle). The absorbance bands in these three 
materials are essentially the same. 
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4.1.4 Inductively Coupled Plasma – Mass Spectroscopy 
Hydroxyapatite-based implants are required to meet a 
specification for maximum levels of heavy metals according to the 
American Society for Testing Materials (ASTM) F 1185 - 88. This 
specification is for ceramic hydroxyapatite intended for surgical 
implants. A semi-quantitative laser ablation high resolution ICP-
MS analysis of two implant samples was conducted.   The results 
indicated that As, cadmium (Cd) and lead (Pb) are below the 
ASTM specifications.  Traces of Hg were detected but in 
concentrations also below the ASTM specification.   
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4.2 ALKALINE PHOSPHATASE ACTIVITY 
At the end of each time period (30, 90 and 180 days) tissues were 
harvested and analyzed for osteoinduction through alkaline 
phosphatase activity, histology, immunohistochemistry and gene 
expression. 
 
4.2.1 Alkaline Phosphatase activity 
 
 
The harvested tissue included connective tissue on the planar 
surfaces.  
Tissues were homogenized on ice in 2ml of homogenizing buffer 
(appendix 1) in sterile elkay tubes (AEC Amersham). The alkaline 
phosphatase activity of the supernatant after homogenization of 
specimens was determined with 0.1M p-nitrophenyl phosphate as 
a substrate at pH 9.3 and 37o C for 30 minutes. Under the assay 
conditions 1 unit of enzyme liberates 1 µmol of p-nitrophenol. 
Alkaline phosphatase is expressed as units of activity per 
microgram protein (Reddi and Huggins, 1972, Matsaba et al., 
2001). Values are means ±standard error of mean (SEM). 
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4.2.2 30 days implantation 
The activity of alkaline phosphatase was generally low in tissues 
generated by all four types of substrata. There were relatively 
small differences in the level of alkaline phosphatase expressed 
and there were no significant differences (Fig. 4 A). Generally, 
alkaline phosphatase activity was relatively higher on day 30 as 
compared to day 90 and was almost non-detectable on day 180 
(Fig. 4 A-C). Alkaline phosphatase activity expressed by Type 1 
was significantly higher at 5% probability level between 30 days 
and 180 days. The minimum amount of alkaline phosphatase 
activity was x units per milligram protein while the maximum was x 
units per milligram protein. There was no significant difference 
between the expressions of alkaline phosphatase within the four 
samples. 
 
4.2.3 90 days implantation 
 
The alkaline activity was relatively low in all the four types of 
substrata. Type 2 showed the highest expression compared to 
Types 1, 3 and 4 and this difference was significant at 5 % 
probability level. Type 2 expression reached maximum of 0.27 
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units per milligram protein (Fig. 4 B). Types 1 and 4 were relatively 
similar and Type 3 was a bit higher though there was no 
significant difference. 
 
4.2.4 180 days implantation 
Only Type 2 and Type 4 samples were implanted for this time 
period. 
The alkaline phosphatase activity was relatively low in both Type 2 
and 4.  
 
Figure 7. The effect of surface geometry on alkaline phosphatase 
activity of tissues generated in the concavities of substrata Types 
1, 2, 3 and 4. Values are means ±SEM. N=6. A: 30 days, B: 90 
days, C: 180 days 
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C. 180 days 
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4.3. Histology and Immunolocalisation 
Harvested tissue for histology was trimmed of adhering muscle 
but included connective tissue on the planar surfaces. The 
morphological hallmarks employed to identify bone tissue were as 
follows: With the modified Goldner’s Trichome stain used in this 
study, bone tissue stains blue on decalcified sections as matrix 
with lacunae filled by osteocytic cells and often, but not always, 
has osteoblastic cells facing the connective tissue matrix highly 
vascularised. The only difference between the original Goldner’s 
stain and the modified one is the counterstaining. The original 
method counterstains with a green stain while the modified 
method counterstains with a blue stain so everything that is green 
representing mineralized bone in the original method will appear 
blue in the modified method.  
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4.3.1 30 days implantation 
Histological analysis revealed condensation of fibrovascular tissue 
and collagenic material, which predates bone formation within the 
concavities of the substratum and morphogenetic events including 
angiogenesis, a prerequisite of bone formation in all four Types of 
substrata. These morphological events occured solely within the 
concavities and not on the planar sites in between concavities. 
(Fig. 5a; A-D). 
Immunohistochemistry showed localisation of OP-1 and BMP-3 in 
Types 2 and 4 substrata. (Fig. 6 B and C). This localisation of 
BMPs/OPs was observed only within the concavities and not on 
the planar surfaces. 
 
4.3.2 90 days implantation 
Morphological and histological examination revealed that bone 
differentiation was exclusively initiated in the concavities of Type 2 
and Type 4 substrata reaching 58.6% in Type 2 and 28.2% in 
Type 4 (Fig. 5b; B and D and Fig. 8 A). Types 1 and 3 showed 
vascular tissue invasion within the concavities of the substratum 
(Fig. 5b; A and C).  
 
4.3.3 180 days implantation 
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Histological results revealed the spontaneous initiation of bone 
formation and vascular invasion within the concavities of both 
substrata Types 2 and 4 (Fig. 5c; A and B). The newly formed 
bone reached 23% and 10 % of newly formed bone area in 
relation to the total area in mm2 of the concavities of Type 2 and 
Type 4 (Fig. 8 B), respectively as measured with the support of a 
computer software (Flexible Image Processing System ® ver. 2.15, 
CSIR, South Africa) installed in a Pentium computer with a colour 
monitor (Ripamonti et al., 1996a, Ripamonti et al., 1997; 
Ramoshebi and Ripamonti, 2000).  
 
Figure 8. Tissue morphogenesis in concavities of the four types of 
substrata on day 30 postimplantation  
30 days 
High power photomicrographs (A-D) 
A: Type 1; B: Type 2; C: Type 3; D: Type 4.  
 
A: Vascular invasion and capillary evidence in close contact with 
the substratum interface (pointy arrows). Mesenchymal tissue 
condensation within the substratum in blue (open arrow heads) 
and giant multinucleated cells (straight arrows) attached to the 
substratum. Original magnification: X101 
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B: Capillary sprouting (pointy arrows) within the network of 
collagen fibers in blue.  Substratum interface (long arrows) 
Original magnification: X101 
 
C: Vascular invasion within collagen (pointy arrows). Substratum 
resorption (long arrows). Original magnification: X50 
 
D:Resorption of the substratum (long arrow). Densely packed 
collagen condensation (open arrow heads) and vascular invasion 
(pointy arrow). Original magnification: X50 
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Figure 9. Low power photomicrographs showing vascular 
invasion within the concavities as compared to the planar surfaces 
in between concavities  (A-D). 
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90 days 
Tissue morphogenesis and spontaneous induction of bone in 
concavities of the substratum on day 90 after heterotopic 
implantation. 
 
Figure 10. High power photomicrographs 
A: Type 1: Pronounced vascular invasion (pointy arrows) within 
collagen fibers. Artefactural separation of soft tissue (small 
arrows). 
Original magnification X101 
 
 B: Type 2: Newly formed bone (arrow heads) covered by 
osteoblastic cells (curved arrows). Osteocityc cells within the 
newly formed bone (straight arrows)  
Original magnification X101 
 
C: Type 3: Vascular invasion (pointy arrows) within collagen (in 
blue) 
Original magnification X101 
 
D: Type 4: Bone induction (arrow heads) in close attachment to 
substratum and covered by osteoblastic cells (curved arrows)  
Original magnification X101 
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Figure 11:Low power photomicrographs of Types 1-4 (A-D) 
successively showing vascular invasion (A and C) within the 
concavities and newly formed bone (B and D) within the 
concavities 
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Figure 12.  Surface area of newly formed bone 
The histological sections of 90 days were analyzed to quantitate 
the percentage area of the newly formed bone in relation to the 
total surface area of the concavity.  
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180 days 
Tissue morphogenesis in concavities of the substratum on day 
180 after heterotopic implantation of Type 2 (A) and Type 4 (B) 
biomaterials.  
 
Figure 13:  High power photomicrographs of tissues generated in 
the concavities of HA types 2 and 4 180 days postimplantation. 
 
A: Newly formed bone attached to the substratum (arrow heads). 
Note Osteocytic cells within new bone (straight arrows) and 
invading tissue within the microporosity of the substratum (pointy 
arrow heads) 
Original magnification:  X101 
 
B: Bone formation (arrow heads) and angiogenic sprouting (pointy 
arrows). Bone-like tissue invading the microporosity of the 
substratum (pointy arrow heads) 
 Original magnification: X101 
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Figure 14:  Low power photomicrographs showing newly formed 
bone within the concavities of tissues generated 180 days 
postimplantation: 
A: Type 2 
B: Type 4 
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Figure 15: The histological sections of 180 days were analyzed to 
quantitate the percentage area of the newly formed bone in 
relation to the total surface area of the concavity.  
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Figure 16. Immunolocalisation of BMP-3 and OP-1 in tissues 
generated within the concavities of Types 2 and 4 substrata on 
day 30 after heterotopic implantation.  
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B: Immunolocalisation of OP-1 in sintered hydroxyapatite 
substratum but harvested from a different animal showing 
immunolocalisation prominently at the hydroxyapatite interface 
(arrows). 
Original magnification X101 
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C: BMP-3 control  
Original Magnification: X101 
 
 
 
 
 
 
 
 
 
 
 
 
concavity 
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D: Immunolocalisation of BMP-3 in osteoblast-like cells 
predominantly immunolocalised at the substratum interface 
(arrows).  
 
Original Magnification:X101 
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Figure 17. Immunolocalisation of BMP-3 and OP-1 in tissues 
generated within the concavities of Types 2 and 4 substrata on 
day 90 after heterotopic implantation.  
A: OP-1 Control 
B: OP-1 imunolocalisation in osteoblast-like cells within the 
concavity (arrows) 
C: BMP-3 Control 
D: BMP-3 immunolocalisation imunolocalisation in osteoblast-like 
cells within the concavity (arrows) 
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4.4 Northern Blot Analyses 
Total RNA was extracted from pooled tissues and hybridized with 
radiolabelled (P32 alpha labeled) cDNA for OP-1, BMP-3, 
collagen type IV, collagen type II, TGF-1 and gamma actin, as 
control. The results are shown in Table 1. Gamma actin was 
expressed strongly at 1.9 kilobases (kb) in all types of substrata 
on all time periods. Collagen type II and TGF-1 were not 
expressed in all types of substrata on all time periods. Signal 
quantitation was performed using a gel documentation system 
(Gel Documentation and Analysis system, Syngene, U.K) 
(Matsaba et al., 2001) and the results were normalized against 
gamma actin as percentages.  
 
4.4.1 30 days implantation 
mRNA analysis for OP-1 showed positive signals at 4.0 kb for all 
Types of substrata (Fig. 7 A and Table 1). However, the signal 
intensity was shown to be different between the different types 
with Type 2 showing the highest expression followed by Type 1. 
Type 3 showed a relatively higher expression of OP-1 than Type 4 
though they are both resorbable. mRNA expression for BMP-3 
was expressed at 3.0 kb and was relatively higher in Types 2 and 
3 as compared to Types 1 and 4 (Fig. 7 A and Table 1). Type IV 
collagen, expressed as two bands, a minor one at 5.1 kb and a 
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major one at 4.0 kb was expressed relatively stronger in Type 2 
and Type 3 as compared to Types 1 and 4. The presence of type 
IV collagen indicates an angiogenic response, which is a 
prerequisite for osteogenesis. Type II collagen and TGF-1 
mRNAs were not expressed (Table 1). 
 
4.4.2 90 days implantation 
Northern blot analysis of tissues generated within concavities of all 
4 Types of substrata showed clear differences in the expression of 
OP-1:   Types 1 and 4 displayed higher mRNA expression when 
compared to Types 2 and 3 (Fig. 7 B and Table 1). OP-1 was 
expressed at 4.0 kb. BMP-3 expressed at 3.0 kb was relatively 
strong in Type 1 through to Type 4 tissue samples (Fig. 7 B and 
Table 1). Collagen type IV was relatively strongly expressed at 
5.1kb and 4.0 kb though differently between the different substrata 
types (Fig. 7 B and Table 1).There was no expression of collagen 
type II and TGF-1 (Table 1).   
 
4.4.3 180 days implantation 
Northern blot analysis showed a relatively low expression of OP-1 
at 4.0 kb in tissues generated in the concavities of both Type 2 
and Type 4 (Fig. 7 C and Table 1). There was no expression of 
BMP-3 in tissues generated from both substrata. Collagen type IV 
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was expressed relatively strong at both 5.1 and 4.0 kb in both 
tissues generated from both samples (Fig. 7 C and Table 1). 
There was no expression of Collagen type II and TGFß1. 
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Figure 18. Northern analysis of mRNA expression of OP-1, BMP-
3 and collagen type IV in harvested tissue generated within the 
concavities of four different types of hydroxyapatite substrata on 
days 30 (A) and 90 (B) postimplantation. (N=6) The -actin 
signals were used as standards for size determination and the 
mRNA levels were normalized against them and expressed as 
relative densitometric units. On 180 days (C) only Types 2 and 4 
were implanted (N=4).  
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Table 1:Summary of results 
 
 Type 1 Type 2 Type 3 Type 4 
Features HA (fine) 
(1 micron 
size) 
HA 
(coarse) 
(>1 
micron 
size) 
HA/ fine 
TCP 
(<100 
micron 
size)  
HA/discrete 
TCP  
(100-300 
micron size) 
Post-implantation findings 
30 days 
HISTOLOGY  - - - - 
ALKALINE PHOSPHATASE 
ACTIVITY 
X X X X 
IMMUNOHISTOCHEMISTRY - X (BMP-
3 and 
OP-1) 
- X (BMP- 
and OP-1) 
NORTHERN BLOTS 
OP-1 
BMP-3 
Collagen IV 
Collagen II 
TGF-beta 1 
 
X 
X 
X 
- 
- 
 
X 
X 
X 
- 
- 
 
X 
X 
X 
- 
- 
 
X 
X 
X 
- 
- 
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90 days 
HISTO  No bone X No bone X 
ALP X X X X 
NORTHERN BLOTS 
OP-1 
BMP-3 
Collagen IV 
Collagen II 
TGF-beta 1 
 
X 
X 
X 
- 
- 
 
X 
X 
X 
- 
- 
 
X 
X 
X 
- 
- 
 
X 
X 
X 
- 
- 
180 days     
HISTO Not 
implanted 
X Not 
implanted 
X 
ALK P Not 
implanted 
X Not 
implanted 
X 
NORTHERN BLOTS 
OP-1 
BMP-3 
Collagen IV 
Collagen II 
TGF-beta 1 
 
- 
- 
- 
- 
- 
 
X 
X 
X 
- 
- 
 
- 
- 
- 
- 
- 
 
X 
X 
X 
- 
- 
 
X= (expression)      - = (no expression) 
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Table2: Intensity of mRNA expression for the probes OP-1, BMP-3, 
Collagen IV, Collagen II, and TGF-ß1 
 
 
TIME 
 
 30 DAYS 90 DAYS 180 DAYS 
HA  1 2 3 4 1 2 3 4 2 4 
Probes            
OP-1 ++ ++ ++ ++ + + + ++ + + 
BMP-3 
 
++ ++ ++ + +++ +++ ++ ++ - - 
Collagen IV + ++ ++ + ++ ++ ++ ++ +++ ++ 
 
Collagen II 
- - - - - - - - - - 
 
TGF-ß1 
 
- - - - - - - - - - 
 
Key: 
- : no expression 
+: low expression 
++:  moderate expression 
+++: High expression 
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5.0 Discussion 
 
 
The molecular and cellular signals that trigger heterotopic 
osteoinduction in porous hydroxyapatite implanted in primates are 
still not well understood. The present study sheds insights into the 
spontaneous induction of bone formation within the concavities of   
hydroxyapatite discs. A process referred to as geometric induction 
of bone formation. 
 
In this study the term geometry refers to concavities of two 
different dimensions (as described in the materials and methods), 
which act as microenvironment for induction of bone. The sizes of 
the concavities were different (figures 1A and 2) to determine the 
suitable diameter for formation of bone. The presence of bone 
was observed within the bigger concavities.  
  
Ripamonti et al. (1999) reported that the geometry of the HA 
substratum plays a critical role in spontaneous induction of bone 
formation. The authors also reported that there was bone 
formation within the concavities of their biomaterials and that the 
presence of BMPs as evaluated by immunolocalisation at the 
interface of the biomaterial suggested two possibilities;  
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1. BMPs may be secreted from the circulation, adsorbed onto the 
hydroxyapatite substratum and induce bone as a secondary 
response.                     
2. The BMPs may be locally expressed within the concavities and 
induce bone formation. 
It is against this background that the present study was 
performed, to investigate the two possibilities.  
 
Four different types of substrata were used in this study, where 
the physical distribution of the co-existing phases was 
manipulated resulting in different compositions and properties of 
the final substrata to be implanted. Briefly, types 1 and 2 ceramics 
were phase pure hydroxyapatite (HA) discs with type 1 prepared 
from a commercial powder (Plasma Biotal). The Type 2 material 
was prepared by a solid state reaction between Merck tri-
calciumphosphate and calcium with a Ca/P molar ratio of 1.67. 
Types 3 and 4 samples consisted of a mixture of HA and TCP in 
the ratio 2:1.  The same HA starting powder that was used in type 
2 biomaterials was also used in types 3 and 4. The microporosity 
of the bulk material of each HA sample was as follows: type 1: 
39%, type 2: 40%, type 3: 38%, type 4: 37%. The porosity was 
determined using Archimedes principle as discussed in materials 
and methods. 
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Significant differences between the implants were particle size 
and distribution of the starting powders. The use of relatively fine 
particles (1 micron) of hydroxyapatite starting powder (Type 1) as 
opposed to a highly crystalline, coarsened (>1 microns) 
hydroxyapatite powder (Type 2), or a fine distribution (<100 
microns) of TCP in hydroxyapatite matrix (Type 3) as opposed to 
discreet (100-300 microns) zones of TCP in hydroxyapatite matrix 
(Type 4) both produced from highly crystalline coarsened powders 
(Thomas et al., 2003). Phase composition and structure were 
verified by XRD, FT-IR and SEM.  
 
The XRDs show that all the HA discs (types 1-4) are phase pure, 
that is, there is only HA (types 1 and 2) or HA and TCP (types 3 
and 4) (figure 5 A-D) in the specified discs. The SEMs show the 
microstructure of the samples (figure 4 A-D). The FTIR show that 
the high temperature processing conditions did not affect the 
bonding groups in the HA (OH groups on the HA are intact) (figure 
6).  
 
The HA implants were harvested at 30, 90 (types 1-4) and 180 
(types 2 and 4) days post-implantation and the induction of bone 
elicited by the implants was examined using alkaline phosphatase 
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activity (figure 7 ), histology (figure 8), and Northern Blots (figure 
18) at each time period. Immunohistochemistry was perfomed at 
30 days post-implantation to determine the presence of BMPs 
within the concavities. Alkaline phosphatase activity was used as 
a marker for bone formation, histological analyses was performed 
to confirm the osteogenic activity imparted by the biomaterials and 
northern blots were performed to determine whether the proteins 
were produced in the concavities or if they are adsorbed from the 
endogenously circulating proteins. 
 
At 30 days alkaline phosphatase activity was low in the tissues 
generated by all the four types of substrata ranging from 0.22 
units per milligram protein to 0.24 units per milligram protein 
(figure 7A). There were no significant differences (5%) between 
alkaline phosphatase activity within the tissues in all four samples 
implanted.  
 
At 90 days postimplantation, alkaline phosphatase activity was 
generally low in the tissues generated by all the four types of 
substrata. The minimum expression was 0.07 units per milligram 
protein while the maximum expression was 0.27 units per 
milligram protein (figure 7B). There were no significant (5%) 
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differences between alkaline phosphatase activity within the 
tissues in all four biomaterials implanted. 
 
Tissues from both types 2 and 4 showed a relatively low activity 
with no significant difference (5%) between each other (figure 7C). 
The minimum activity expressed was 0.05 units per milligram 
protein and the maximum activity was 0.09 units per milligram 
protein. 
 
Comparatively, there was no significant difference between 
alkaline phosphatase activity expressed by tissues generated by 
Type 1 samples at 30 days and 90 days. Type 2 samples at 30 
and 90 days showed a significantly higher amount of alkaline 
phosphatase at 5% probability level compared to 180 days. 
Alkaline phosphatase. has been documented as a marker of bone 
formation (Reddi and Huggins). The authors also reported that 
alkaline phosphatase activity is low during early bone formation, 
increases with increase in bone formation then decreases during 
bone marrow formation.   
 
Histological analyses showed condensed fibrovascular tissue and 
collagenic material within the concavities of all the four types of 
HA substrata at 30 days postimplantation (figure 8). Studies by 
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Ripamonti and Ripamonti et al. on porous hydroxyapatite 
harvested at one month (Ripamonti et al., 1992b), two months 
(Ripamonti et al., 1993), three months (Ripamonti, 1991; 1996), 
six months and nine months (Ripamonti, 1991) showed that bone 
differentiation in porous hydroxyapatite occurs by day 60 after 
implantation.  
 
The other important observation within the concavities of all 
harvested HA biomaterials at 30 days was angiogenesis (figure 8). 
Angiogenesis, which refers to the sprouting of blood vessels from 
existing ones, as well as vascular invasion, was a prominent 
histological feature in this study as shown in histology 
photomicrographs in the results section (figure 8 A-D and 
figure10A and C). Sprouting blood vessels play a critical role in 
bone formation because blood is important for delivering oxygen, 
nutrients and BMPs/OPs to the site of induction (Reddi, 2000; 
Gerber and Ferrare, 2000; Colnot and Helms, 2001).  
 
The observed angiogenesis within the concavities of the substrata 
in this study indicate that the specific geometry of the substrata 
induce vessel ingrowth and capillary sprouting within the 
mesenchymal tissue that penetrates the porous spaces eventually 
leading to bone induction. Ripamonti et al. (1993) reported data 
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suggesting that osteogenetic vessels as defined by Trueta (1963) 
might provide a temporally regulated flow of cell populations that 
can express the osteogenic phenotype (Ripamonti et al., 1999; 
Ripamonti et al., 1993).  
 
Histological examination showed that bone differentiation was 
localized within the concavities of the substrata and not on the 
planar surfaces as shown in the photomicrographs of types 2 and 
4 in the results section (figure 11 B and D). Modified Goldner’s 
Trichome stain was used to identify bone tissue. With this method 
bone tissue stains blue on decalcified sections as matrix with 
lacunae filled by osteocytic cells and often but not always, has 
osteoblastic cells facing the highly vascularised matrix of the 
connective tissue. Only HA types 2 and 4 samples induced bone 
formation at 90 days while sample types 1 and 3 did not show any 
bone formation at this time period but showed angiogenesis 
(figures 10 B and D and 11 B and D).  
 
The amount of newly formed bone in type 2 concavities reached 
58.2 % while that generated in type 4 reached 28.2 % 90 days 
postimplantation (figure 12). The amount of newly formed bone 
was calculated as described in the materials and methods. Newly 
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formed bone was measured as new bone area in relation to the 
total area of the concavity in mm2.  
 
A 180 days postimplantation bone formation was observed in both 
HA types 2 and 4. The amount of newly formed bone reached 
23% in type 2 and 10 % in type 4 (figure15). Angiogenesis was 
also observed within the concavities (figures 13 and 14).  
 
Immunohistochemistry showed expression of BMP-3 and OP-1 
within the concavities in HA types 2 and 4, suggesting the 
presence of BMPs within the concavities at 30 days post 
implantation (figure 16). This result agrees with the results of 
Ripamonti et al. (1999) where the authors also suggested the 
presense of BMPs within the concavities of biomaterials at 30 
days post-implantation. OP-1 and BMP-3 were also localised 
within the concavities 90 days postimplantation (figure 17). 
However due to the limitations of the technique used, there was 
some non-specific staining within the concavities as well.  
  
The question remains as to why no bone formation was observed 
within the concavities of HA types 1 and 3 at 90 days post-
implantation.  The results suggest that particle size and 
distribution of the starting powders may have played a critical role 
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in the induction of bone formation. As has been mentioned, the 
differences between types 1, 2, 3 and 4 HAs was particle size and 
distribution of the starting powders. Types 1 and 3, which were 
both made of fine particles of starting powders did not show any 
bone formation even in the presence of BMPs. Types 2 and 4 
biomaterials, which were both made of coarse starting powders, 
showed bone formation at 90 days post-implantation.  
These results suggest that particle size may play an important role 
in bone formation.  
Complementary DNA (cDNA) probes namely, BMP-3, OP-1, 
Collagen type II, Collagen type IV and TGF-1 were used to study 
gene expression of markers of bone formation. The results 
showed clear differences in gene expression of the specific 
markers of bone formation, i.e BMP-3 and OP-1 mRNA 
expression (figure18). Collagen type IV, a marker for angiogenesis 
was also expressed (figure 18). Collagen type II and TGF-1 were 
not expressed at all time periods in all biomaterials. 
 
OP-1 and BMP-3 expression were observed. OP-1 mRNA was 
expressed moderately by all types 1-4 biomaterials while BMP-3 
mRNA was expressed moderately by types 1-3 and relatively 
lower by type 4 (figure18). Collagen type IV was expressed 
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moderately by types 2 and 3 and low by types 1 and 4. Collagen 
type II and  
 
TGF- 1 were not expressed in all HA types (table 1). 
OP-1 expression was relatively low in HA types 1-3 and moderate 
in type 4 (figures). BMP-3 expression was relatively high in types 
1and 2 and moderate in types 3 and 4. Collagen type IV as 
relatively moderate in all types 1-4 (figure 18). Collagen type IV 
and TGF-ß1 were not expressed in all HA types (table 1). 
 
There was no expression of BMP-3 mRNA in both HA types 2 and 
4. OP-1 mRNA expression was low in both HA types 2 and 4. 
Collagen type IV mRNA expression was relatively high while 
Collagen type II and TGF-ß1 mRNAs were not expressed.  
 
Generally, the expression of OP-1 and Collagen type IV was 
similar both at 90 and 180 days though it differed at 30 days 
(figures). BMP-3 expression was seen only at 30 days and 90 
days, not 180 days (figures). OP-1 was relatively high at 30 days, 
moderate at 90 days and high at 180 days (figure 18). Collagen 
type IV was expressed at all time periods and in all types of HA 
implanted; moderate at 30 days and high at 90 and 180 days 
(figure 18). This result supports the histological results of all HA 
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types implanted at all 3 time periods where angiogenesis was one 
of the major observations (figure 18).  
 
There is a disparity between the histological results and the 
northern blot results. The northern blot results show expression of 
BMPs in all types of HA implanted at all time periods (figure18) 
and yet histologically HA types 1 and 3 did not induce any bone 
formation at 90 days (figures 9 and 10) and all types 1-4 did not 
induce bone formation at 30 days. Further studies need to be 
done to investigate this disparity. 
 
The expression of collagen type IV (figures), which is a major 
component of basement membranes (Paralkar et al., 1990), could 
give insights towards understanding the morphological evidence 
of angiogenesis localized in the mesenchymal tissue invading the 
concavities of the substrata. Angiogenesis is a pivotal event in 
bone development and in adult bone repair. In both situations, 
blood vessels grow into hypertrophic cartilage and erode it to 
produce a scaffold on which osteoblasts settle to produce bone. 
This vascular response is essential for normal bone formation and 
bone repair.  
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There may be other factors that may have inhibited bone 
formation within the concavities of all HA types at 30 days as well 
as types 1 and 3 at 90 days even in the presence of BMP 
expression. This may be explained in further studies into the 
mechanism of spontaneous induction of bone by HA biomaterials. 
Expression of BMPs in the absence of bone formation has been 
reported (Autzen et al., 1998; Barnes et al., 1995; Hatakeyama et 
al., 1997; Clement et al., 1999).  
 
The biomaterials cascade of bone formation involves invasion of 
the concavities by capillaries resulting in angiogenesis, followed 
by attachment of mesenchymal cells to the substrata which lead to 
differentiation of osteoblast-like cells and finally, expression of 
BMPs/OPs and induction of bone formation. Collagen type II and 
TGF-1 were not expressed. Collagen type II is a marker of 
chondrogenesis, and hence was not expressed suggesting that 
the cascade of bone formation in this study was intramembranous.  
 
 
The geometry of the substratum may play a part in initiating a 
microenvironment that is angiogenic hence conducive for 
induction of bone in the presence of BMPs within the concavity at 
a certain time period as shown by HA types 2 and 4. However, HA 
types 1 and 3 did not show any bone formation within the 
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concavities even in the presence of BMPs which suggests that 
there are other factors that also play a critical role in initiating or 
inhibiting bone formation within the HA concavity.  
 
One factor that has been shown in this study to play a role in the 
induction or inhibition of bone formation within the concavities is 
the particle size and distribution of the starting materials where the 
biomaterials that were made with relatively fine starting powders 
(types 1 and 3) did not induce bone formation as compared to 
those that were constructed with relatively coarse starting 
powders (types 2 and 4).  
 
While all the results observed in this study are significant, they did 
not provide sufficient basis for explanation for the fact that no 
bone formation was observed in tissues harvested from HA 
sample types 1 and 3 at 90 days suggesting that further 
investigations have to be made into biomaterials to explain this 
behaviour. Another limitation of the study was the decision to 
exclude implantation of HA types 1 and 3 for harvesting at 180 
days postimplantation based on the fact that bone formation was 
not observed in the implants 90 days post-implantation. In future 
studies, all biomaterials implanted for one time period should be 
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implanted for all periods irrespective of how they behave in 
between time periods. 
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6.0 CONCLUDING STATEMENTS 
The results of this study revealed that the geometry, which in this 
study refers to the concavities of specific dimensions, acts as a 
regulator allowing or inhibiting cell differentiation. There are more 
mechanisms that need to be studied to unravel this phenomenon 
of spontaneous bone induction by the geometry of the substratum. 
The present study, however, has established that it is the effect of 
the substratum per se regulating and driving specific gene 
expression and the sequential cascade of events leading to bone 
formation by induction within the concavity in the heterotopic sites 
of adult baboons. The results of this study suggest that the BMPs 
are localised within the concavity and initiate bone formation as a 
secondary response. Further molecular studies need to be carried 
out using different animal models to shed further insights into the 
geometric induction of bone formation. This would be of critical 
importance in clinical contexts.  
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Appendix 1 
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Substrate solution- 0.01M para-nitrophenyl phosphate (PNPP) in 
distilled water 
Buffer solution- 0.1 M sodium barbitone in distilled water pH 9.3 
Base solution- 0.1 N (Sodium hydroxide) NaOH in distilled water 
Homogenising buffer- 0.15 M (Sodium chloride) NaCl, 0.003 M 
Sodium  
 
bicarbonate (NaHCO3 ) in distilled water 
 
 
Appendix 2 
Bovine serum albumin (BSA) stock: 1 mg/ml in distilled water 
Protein stock solution: 2% Na2Co3 (w/v) in 0.1 N NaOH 
Copper Reagent: To 100 ml of protein stock solution, were added 
1 ml of 2% Na Tartrate and 1 ml of 1% (w/v) CuSO4.5 H2O. 
Phenol reagent: 2 N Folin Ciocalteau diluted 1:1 with distilled 
water. 
 
Appendix 3 
Stable Iron Haematoxylin 
Fuschin Ponceau 
Orange G Molybdate 
Methyl Blue 
 
 
 
 
 
Appendix 4 
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Buffer : Sodium Chloride: 17.0 g 
Di-sodium Hydrogen Orthophosphate: 2.8 g 
Potassium Dihydrogen Orthophosphate: 0.4 g 
Potassium Chloride: 0.4 g 
Distilled Water: 2000 ml 
 
Appendix 5 
 
0.1% diethylpyrocarbonate (DEPC) in milli Q water 
Tri- Pure isolation reagent 
Chloroform 
100% isopropanol 
75% ethanol 
lauryl sarcosine/EDTA solution 
 
 
Appendix 6 
Electrophoresis buffer, 5X concentrate 
0.1 M  Mops 
40 mM sodium acetate, pH 7.0 
5 mM EDTA 
Gel loading buffer: 
50% glycerol 
1 mM EDTA 
0.25% bromophenol blue 
0.25% xylene cyanol FF 
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Appendix 7 
 
Formamide 
 
Formaldehyde 
 
RNA gel loading buffer 
   
0.5µg/ml ethidium bromide 
 
DEPC treated water 
 
 
 
Appendix 8 
 
Formamide 
 
Formaldehyde 
   
RNA gel loading buffer 
 
0.5µg/ml ethidium bromide 
 
DEPC treated water 
 
 
Appendix 9 
  
Luria Bertani (LB) medium 
Agar 
CaCl2 
Glycerol 
 
 
Appendix 10 
 
LB medium 
Distilled water 
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Appendix 11 
 
High Pure Plasmid Kit 
LB medium 
Tris-HCl buffer 
Appendix 12 
Tris borate (TBE) buffer 
DNA megaprime labeling kit RPN 1606 
alpha- 32P dCTP 
DNA purification kit 
 
Appendix 13 
 
Sonicated fish sperm DNA 
QuikHYB 
SSC (Saline Sodium Citrate) 
SDS (Sodium Dodecyl Sulphate) 
